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Es kann die Ehre dieser Welt 
 
Es kann die Ehre dieser Welt 
Dir keine Ehre geben, 
Was dich in Wahrheit hebt und hält, 
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Ist all dir wenig nütze. 
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Magst du dem Eitlen gönnen; 
Das aber sei dein Heiligtum: 
Vor dir bestehen können. 
 






Table of contents 
Inhalt  
Acknowledgements ................................................................................................................................... X 
Abstract ........................................................................................................................................................ XI 
List of figures ............................................................................................................................................ XII 
List of tables ............................................................................................................................................ XIII 
Abbreviations ......................................................................................................................................... XIV 
1 Introduction ................................................................................................................................... 1 
1.1 Background ................................................................................................................................. 1 
1.1.1 Folate Receptor α ............................................................................................................. 2 
1.2 Extracellular Vesicles .............................................................................................................. 4 
1.2.1 Exosomes ............................................................................................................................ 5 
1.3 Exosomes in clinical application ......................................................................................... 6 
1.3.1 Purification and characterization .............................................................................. 7 
1.3.2 Drug loading ....................................................................................................................... 8 
1.3.3 Exosome application and distribution .................................................................. 10 
1.4 Model diseases suitable for the screening of exosomal transport vehicles .... 11 
1.4.1 Late infantile neuronal ceroid lipofuscinosis ..................................................... 11 
1.4.2 Biopterin Disorders ...................................................................................................... 12 
1.4.3 FRα-conjugated nanoparticles ................................................................................. 15 
1.5 Aims of the study ................................................................................................................... 16 
2 Materials and methods ........................................................................................................... 17 
2.1 Materials.................................................................................................................................... 17 
2.2 Methods ..................................................................................................................................... 23 
2.2.1 EV sample preparation and cell culturing ........................................................... 23 
2.2.2 Fast performance liquid chromatography .......................................................... 24 
VII 
 
2.2.3 EV-Preparation by DC ................................................................................................. 26 
2.3 Protein biochemistry ............................................................................................................ 26 
2.3.1 Purification of PTPS from E. coli recombinant production strain .............. 26 
2.3.2 Purification of TPPI ...................................................................................................... 27 
2.3.3 BCA assay ......................................................................................................................... 28 
2.3.4 SDS-PAGE and Western Blot analysis ................................................................... 28 
2.4 Experimental methods ........................................................................................................ 29 
2.4.1 Analysis of density by centrifugation on a sucrose gradient ....................... 29 
2.4.2 Nanoparticle tracking analysis ................................................................................ 30 
2.4.3 Electron microscopy .................................................................................................... 31 
2.4.4 Uptake analysis of EVs by epithelial cells with flow cytometry .................. 32 
2.5 Animal experiments .............................................................................................................. 33 
2.5.1 Ptstm1Thny/ Ptstm1Thny mouse line .............................................................................. 33 
2.5.2 Vesicle replacement therapy of FRα-presenting and PTPS-loaded vesicles
 34 
2.5.3 Analysis of the biodistribution by organ screening ......................................... 35 
2.5.4 Analysis of the locomotor activity by tracking with an infrared sensor . 36 
2.5.5 Analysis of the strength and motor coordination by Rota rod experiment
 36 
3 Results ........................................................................................................................................... 37 
3.1 Purification of extracellular vesicles by chromatographic approaches ........... 37 
3.1.1 SEC followed by IMAC for purification of his-tagged vesicles ..................... 37 
3.1.2 IEC for purification of unmodified vesicles ......................................................... 38 
3.1.3 Improved purification of not modified vesicles by SEC followed by IEC 39 




3.2 Method outcome, purity of the product and reproducibility of the method .. 42 
3.2.1 Outcome of the different EV isolation protocols ............................................... 42 
3.2.2 Purity of the different EV-preparations ............................................................... 45 
3.3 Vesicle characterization ...................................................................................................... 46 
3.3.1 Characterization of protein marker ....................................................................... 47 
3.3.2 Size determination of the vesicles .......................................................................... 50 
3.3.3 Characterization of single vesicles ......................................................................... 51 
3.3.4 Density of the different EV-preparations in comparison .............................. 53 
3.3.5 Verification of FRα on the surface of the isolated vesicles ........................... 56 
3.3.6 Analysis of biological performance by EV uptake ............................................ 58 
3.4 Cargo loading ........................................................................................................................... 59 
3.4.1 Loading experiments with the TPPI assay .......................................................... 60 
3.4.2 Endogenous loading of PTPS .................................................................................... 63 
3.5 Analysis of biodistribution of the vesicles after intranasal application ........... 65 
3.6 Investigation of the drug vehicle capacity of the FRα-presenting EVs 
equipped with therapeutic cargo ................................................................................................. 68 
3.6.1 Analysis of the overall performance of the EV-treated KO mice ................ 71 
4 Discussion .................................................................................................................................... 74 
4.1 Successful isolation of EVs in a high quality by chromatographic approach . 74 
4.2 Loading of therapeutic proteins to vesicles by membrane targeting ................ 77 
4.3 Uptake of FRα-presenting EVs .......................................................................................... 80 
4.4 Biodistribution of intranasally administered exosomes ........................................ 80 
4.5 Drug delivery capacity of PTPS carrying and FRα-presenting exosomes........ 82 
4.6 Outlook ...................................................................................................................................... 83 
5 Bibliography................................................................................................................................ 84 
IX 
 






Das Promotionsvorhaben war für mich ein langer Weg, auf dem mich viele Menschen 
begleitet und unterstützt haben. Ich möchte mich bedanken bei  
Frau Professor Gärtner für die Möglichkeit in ihren Laboren arbeiten zu 
können und die umfangreichen Unterstützungen.  
Professor Robert Steinfeld für dieses großartige Projekt, die Betreuung und die 
Freiheit auch meine eigenen Ideen umsetzen zu dürfen.  
Jan Wehland und der Arbeitsgruppe von Professor Diederichsen für die 
freundliche Einweisung in die Arbeit mit Liposomen.  
Anne Stündl und der Arbeitsgruppe von Frau Schneider für die Möglichkeit 
den Nanosight LM10 nutzen zu können.  
Frau Professor Blanche Schwappach und Herr Professor Silvio Rizzoli für 
wirklich hilfreiche und inspirierende Besprechungen. 
allen Tieren die im Rahmen meines Projektes geopfert wurden, allen voran 
meiner ersten Knockout-Maus #188, Rocks.  
allen Mitarbeitern der Tierhaltung, jedoch insbesondere Tanja Huttanus. Ohne 
ihre Hilfe wäre die Arbeit mit der pts-Linie nicht möglich gewesen.  
meinen Kollegen aus dem Labor der Pädiatrie für das angenehme 
Arbeitsklima, die Geduld und Hilfe. Vor allem möchte ich Kathrin Schreiber und Tanja 
Wilke hervorheben. Sie haben auch bei meinen praktischen Arbeiten mitgeholfen und 
mich vertreten. Dadurch waren sie eine unglaubliche Unterstützung.  
meinem Megaoffice, Rose, Karina, Annika, Maria, Julia, Thomas, Ignacio, Lydia 
und Kristina. Es war wirklich eine schöne Zeit mit euch, das Kochteam, die 
Sporteinheiten, der Kleiderkreisel, die Hilfe bei allen Herausforderungen und 
Matheaufgaben und die perfektesten aller Dinner. Ich bedaure, wahrscheinlich nie 
wieder in einer solchen Gemeinschaft arbeiten zu werden. 
meinen Freunden, in und außerhalb Göttingens, für ihre Unterstützung und 
das Verständnis in stressigen Phasen. 
meinem Freund Benjamin für das offene Ohr, sein Verständnis und Weisheiten 
aus Rocky I-VII. 
meinen Geschwistern, nicht. Tatsächlich habt ihr mir nicht aktiv geholfen. 
Jedoch bin ich unendlich dankbar dafür, dass es euch gibt, jeden einzelnen. 




Extracellular vesicles (EV) for the therapeutic application are of growing scientific 
interest. But even though the number of clinical trials on EVs almost doubled from 29 
to 52 within 2017, the number of trials with therapeutically applied EVs was only two. 
In this project, the performance of folate receptor alpha (FRα) presenting EVs as drug 
vehicles in neuropediatric disorders was investigated. FRα was proven to be the key 
player for the transport of folates to the brain. On that account, FRα-presenting EVs 
are predestined to be used as vehicles for therapeutics which are naturally not 
processed across the blood-cerebrospinal fluid-barrier. The application of EVs as 
carriers is hampered by the complex nature of this biological material and a still 
strongly evolving field of methodology. In this project, central questions of the 
production of EV therapeutics were addressed: preparation, cargo loading and 
biological screening. For a reliable purification of large amounts of highly pure EVs, a 
unique fast performance liquid chromatography purification method for his-tagged 
vesicles was established. This method is made up by size exclusion chromatography 
followed by immobilized metal affinity chromatography. The preparation was 
comprehensively characterized and verified as exosome-like vesicles. In the second 
phase, the loading of therapeutic cargo was performed. While artificial loading of 
therapeutic cargo based on the introduction of pores into the vesicles and addition of 
the drug protein had low efficiency, better results could be achieved by endogenous 
loading by means of a membrane targeted drug protein. In choroid plexus cells from 
rat an increased uptake of these modified EVs in comparison to native vesicles could 
be proven. This uptake tendency could not be manifested for the brain in in vivo 
experiments using adult mice. Finally, the neuronal drug delivery capacity of these 
promising vehicles was screened in a mouse model of a biopterin disorder. In these 
experiments, an enzyme replacement therapy delivered by EVs could be realized for 
the first time. The mice had a significant improvement in their health status and 
performed better in a behavioral assay in comparison to not exosome-treated 
animals. By this successful treatment, evidence for an EV based drug delivery to the 
central nervous system of an enzyme replacement therapy was given.  
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Even though the heart is seen as the driving force of an organism, the brain is the 
centrum of most actions, decisions and emotions. This central system is a very 
sensitive organ with its own physiological milieus and a limited capacity for 
regeneration. For these reasons, the central nervous system (CNS) is protected by 
barriers like the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier 
(BCSFB). These very selective and effective protection systems are major hurdles for 
the treatment of CNS disorders. Despite an increase of scientific efforts, the 
development rate of new drugs does not comply with the growing knowledge of the 
nervous system. Still most new drugs are not able to pass the BBB (Pardridge, 2003).  
William Pardridge nicely outlined the strategies to overcome such biological barriers. 
In general, he described four delivery strategies (Pardridge, 2003). The first and most 
straightforward one is the modification of the molecule properties. Particles smaller 
than approximately 400 Da with lipophilic characteristics are able to pass the BBB 
(Pardridge, 2005). Another strategy is the disturbance of protecting mechanisms with 
an additional drug, like the hindrance of an active efflux of therapeutic molecules 
(Pardridge, 2003). The third approach is the mimicking of intrinsic molecules that are 
transported to the brain by carrier proteins, as for example, L-Dopa is transported by 
the type 1 large neutral amino acid transporter (Pardridge, 2003). The fourth strategy 
is to use existing receptor-dependent transport systems like the insulin receptor or 
the transferrin receptor and to mask or hide the therapeutic molecules just like in a 
Trojan Horse (Pardridge, 2003). The fourth strategy resembles most the principal 
strategy that is presented in the following. 
1.1 Background 
In 2013, Professor Steinfeld’s working group was able to resolve the function of folate 
receptor α (FRα) in the brain (Grapp et al., 2013). Folates are essential metabolites 
that mammals take up with their diet. They are absorbed by the small intestine and 




liver. 5MTHF is then distributed in the blood to all organs. Enzymes functionally 
depending on folates are involved in the metabolic cycles for the synthesis of 
thymidylate and purines, precursors for nucleotides and methionine an 
interconversion of the amino acids serine and cysteine (Pietrzik et al., 2010). Folate 
deficiency or disruption of the folate metabolism leads to severe diseases. Lack of 
sufficient folate supply is associated with serious neural-tube defects, malformations 
evolving during embryogenesis by failure of closure of the neural tube. A 
supplementation of folic acid, a synthetic form of folate, led to a reduction of the 
prevalence in various countries (Imbard et al., 2013). 
The transport of folates into cells is performed by different transport mechanisms. 
The major transporter of folates is the ubiquitously expressed reduced folate carrier. 
This antiporter is able to transport folate into cells at physiological pH of 7.4 (Zhao et 
al., 2011). The proton-coupled folate transporter is less abundant and has a transport 
optimum at low pH (Zhao et al., 2011) and is rather active in the digestive system for 
folate uptake. The third transport mechanism refers to the folate receptors (FRs). 
These have the highest affinity to folates with a dissociation constant Kd of 10 pM 
(Wibowo et al., 2013).  
1.1.1 Folate Receptor α  
There are at least three types of FRs: FRα, β and γ. FRα and β are attached to a 
glycosyl-phosphatidylinositol(GPI)-anchor and are incorporated into lipid rafts of the 
cell membrane (Ikezawa, 2002). FRγ is constitutively secreted by lymphoid cells (Hao 
et al., 2003) and because of an inefficient anchoring sequence not attached to 
membranes (Shen et al., 1995). FRα is expressed in epithelial cells of the choroid 
plexus, the kidney and mammary gland. It is upregulated in a variety of malignancies 
of these cells and also in malignancies of other origin (Ross et al., 1994). FRβ is 
present in neoplastic tissues of non-epithelial origin (Ross et al., 1994), FRα is used 
for diagnostic imaging of FRα-positive tumors (Ke et al., 2003) and FRα-binding 
partners, also called antifolates, were designed to specifically target cytotoxic 




Grapp et al. identified several mutations in the FRα-encoding gene FOLR1 in patients 
with reduced concentrations of 5MTHF in the cerebrospinal fluid (CSF) (Grapp et al., 
2012). This way, FRα could be identified as the key protein in the transport of folates 
to the brain. Furthermore, they could show that FRα is internalized at the basolateral 
side of the choroid plexus in early endosomal vesicles. These vesicles are processed to 
GPI-enriched early endosomal compartments (GEEC) and to multi vesicular bodies 
(MVB). MVB fuse with the apical side of the choroid plexus cell layer and the vesicles 
are released as exosomes to the CSF (Grapp et al., 2013). Furthermore, the 
researchers could prove the distribution of these vesicles throughout the whole brain 
parenchyma indicating that FRα-containing vesicles are used as transport vehicles for 
the supply of the CNS with folates. A scheme of the uptake mechanism is displayed in 
figure 1.1. 
 
Figure 1.1: Schematic overview of FRα transcytosis in the choroid plexus.  
5MTHF (F) binds to FRα at the basolateral side of the choroid plexus and is being internalized 
to GPI-enriched early endosome compartments (GEEC) and processed through multi 
vesicular bodies (MVB). FRα-positive vesicles are formed by invagination to endosomal 
vesicles. These FRα-positive vesicles are released to the CSF after fusion of the MVB with the 




1.2 Extracellular Vesicles  
Exosomes are one of three types of extracellular vesicles (EVs); the other subtypes are 
apoptotic bodies and microvesicles. Apoptotic bodies evolve during cell apoptosis and 
are 1-2 µm of size. These vesicles can be easily distinguished according to their size. 
Microvesicles form by outward budding of the cellular membrane and have more 
characteristics, like size and some protein markers, in common with exosomes. 
Exosomes originate from the endosomal pathway. 
The scientific field on extracellular vesicles is strongly emerging. Especially 
publications on exosomes increased in the last decades as shown in figure 1.2. The 
interest in exosomes grew rapidly since, it became obvious that exosomes are an 
important communication tool and are specifically internalized by cells (Pan and 
Johnstone, 1983). Until this time, it was rather thought of them as waste disposal 
systems (Sutaria et al., 2017). In general, no unique protein marker for exosomes 
could be clearly defined yet and the Journal of Extracellular Vesicles recommends 
referring to extracellular vesicles rather than using the term exosomes (Gould and 
Raposo, 2013). It must be clear that EVs are a very diverse group of extracellular 
organelles and must be classified according to their biogenesis pathway (Sutaria et al., 
2017). 
 
Figure 1.2: Development of research on extracellular vesicles.  
The number of publications on extracellular vesicles increased notably from the year 2004 
until the time of analysis in December 2013. In 2011 the International Society of Extracellular 
Vesicles (ISEV) recommended the use of the general term EVs and the use rapidly grew. The 
numbers were normalized to number of scientific medico-biological publications per year 





Most cells release exosomes. Consequently, all major physiological fluids like breast 
milk, urine or blood plasma contain exosomes. They are bilayer membrane vesicles 
with a size of 50-1000 nm (Raposo and Stoorvogel, 2013) and a density of 1.13-
1.19 g/ml (Kourembanas, 2015). The exosomal membrane forms from inward 
budding of the endosomal vesicle membrane enclosing intercellular components from 
the cytosol. Still the exosomal membrane has a different composition than the cell 
membrane of origin. Disaturated phospholipids are enriched and the protein/lipid-
ratio is higher than in the parental cell, resulting in an increased rigidity (Record et al., 
2014). Cholesterol, ceramide and phosphoglycerides are concentrated in exosomes 
and might be one of the reasons for their stability (Kourembanas, 2015). Lipid sorting 
occurs in the phase from the early to the late endosomal stage, at the MVB-level 
(Subra et al., 2007). Lipid rafts are cholesterol-rich membrane regions that are known 
to contain high amounts of GPI-anchored proteins (Sharma et al., 2004). The 
intercellular sorting of FRα as a GPI-anchored protein has been demonstrated to be 
targeted to GEEC (Sabharanjak and Mayor, 2004).  
Exosome formation is supported by syndecan-syntenin interacting with ALIX for the 
endosomal membrane budding. The endosomal-sorting-complexes-required-for-
transport (ESCRT) machinery is involved in the exosome biogenesis, but there is also 
a ESCRT-independent pathway (Zhang and Yang, 2018). Resulting from this, MVB-
specific proteins like Alix and TSG101, and endosome-associated proteins like 
annexins and flotillin are regarded as exosome markers (Kourembanas, 2015, Raposo 
and Stoorvogel, 2013). 
Exosomes contain proteins from the Golgi complex, DNA and different types of RNA, 
like tRNA, small interfering RNA and miRNA. This content is selectively incorporated 
during exosome biogenesis and even present in different amounts than in the 
parental cell. These observations suggest a specific packaging of exosomes for 
information transfer with other cells (Raposo and Stoorvogel, 2013). Some MVB are 





Figure 1.3: Exosome biogenesis - from formation to release.  
Exosome formation can be separated in three stages: the first includes the endosome 
formation from the cell membrane, the second makes up the exosome formation from inward 
budding of the endosomal membrane and its procession to MVB. At last, these vesicles are 
released after fusion of the MVB with the cell membrane. Some late endosomal compartments 
are also directed to lysosomes (Kourembanas, 2015).  
1.3 Exosomes in clinical application 
Exosomes are already in clinical application. There are many publications on the 
feasibility of exosomes as diagnostic and prognostic tools especially for cancers like 
mamma carcinoma, pancreatic cancer or glioblastoma (Soung et al., 2017). 
In addition, there have been promising results on the application of exosomes for 
vaccination. For example, in a phase II trial, exosomes were used for activation of the 
immune system against tumor cells. Patient monocyte derived dendritic cells were 
isolated and the expression of CD40, CD80, CD86, and CD54 induced (Viaud et al., 
2011). An increase of natural killer cells and a stabilization of tumor progression of at 
least 4 months in patients with inoperable non-small cell lung cancer could be 
achieved (Besse et al., 2016). Beside their capacity to function as diagnostic or 
immunological tools, exosomes are excellent candidates for drug delivery because of 
their stability and the possibility to transport cargo. There are phase I trials on 




administered to the patient (Hosseini et al., 2015). In these experiments the feasibility 
and safety of EVs derived from dendritic cells could be proven. 
In general, the application of EVs in clinic is possible. They would be regarded as 
biopharmaceuticals and would be covered by guidelines for the manufacturing and 
the evaluation of biological medicine, that are existing in the United States, the 
European Union and Australia. Maybe more specific guidelines for EVs will be needed 
(Lener et al., 2015). 
1.3.1 Purification and characterization  
Despite the increasing interest in EVs, the tools for EV isolation, their modification 
and application are still in their infancy. A major challenge in the work with exosomes 
is their intermediate size-range. They are smaller than cells, but bigger and 
structurally more complex than proteins.  
Exosomes are mainly purified regarding their size and density, less common is the 
isolation by immunoaffinity or surface charge. The most common protocol for EV 
isolation is differential centrifugation (DC) (Witwer et al., 2013). In several 
centrifugation steps bigger particles are pelleted and discarded until in a final 
ultracentrifugation step, exosomes are isolated. This product can be further purified 
with an additional centrifugation step by washing or by subjection to a density 
gradient.  
The application of density gradient centrifugation with an additional purification by 
ultrafiltration or a previous washing step have been regarded as superior because of 
an increased purity (Greening et al., 2015) and a reduced formation of EV aggregates 
(Momen-Heravi et al., 2013).  
More innovative but also requiring more sophisticated equipment is the application of 
flow field-flow fractionation. This method is based on a thin layer of flow in the one 
direction of the particulate sample while an additional flow in another direction is 
applied across the driving flow. The particles are separated according to their 




small volumes of 1-2 ml, but a repeated application and pooling of the resulting EV-
preparations might allow its application for the production of high scales (Petersen et 
al., 2014).  
From experiences of the virus field, another method based on polyethylene-glycol 
(PEG) precipitation has been established and is widely used for exosome isolation 
(Taylor et al., 2011, Zlotogorski-Hurvitz et al., 2015, Rekker et al., 2014). EVs bind to 
PEG because of negative surface charge and can be easily centrifuged at low speed 
and isolated. Compared to isolation by ultracentrifugation, the sheer-stress is reduced 
and less equipment is needed. The main disadvantage is the impossibility to remove 
PEG and the precipitation of contaminating proteins (Kotmakçı and Akbaba, 2017).  
For a characterization of exosomes, the Journal of Extracellular Vesicles names 4 
minimal requirements. Only covering all areas can ensure to reliably work on EVs 
(Lötvall et al., 2014). 
1. General characterization of proteins enriched in EVs and proteins absent by 
Western Blot analysis or flow cytometry 
2. Analysis of single vesicles for the shape and homogeneity by electronic 
microscopy or atomic force microscopy  
3. Analysis of the size distribution by nanoparticle tracking analysis or 
 dynamic light scattering  
4. Study of the biological activity 
1.3.2 Drug loading 
Since the biological effect of many therapeutics like oligonucleotides, proteins or 
small molecules is hampered by fast clearance, immunologic reaction and unspecific 
targeting, there are many efforts to load drugs into EVs. Other approaches like 
packing in liposomes, viral vectors for nucleotides and peptide conjugation remain 
problematic (Sutaria et al., 2017). 
In literature, experts generally speak of exogenous and endogenous loading. While 
exogenous loading is performed with purified or isolated vesicles, endogenous 




vesicles. In context of exogenous loading, terms of active and passive loading are used 
(Sutaria et al., 2017), defining passive loading as the incubation of the pure vesicles 
with the drug and active in means of forming pores into the membrane. These terms 
are misleading, since active loading could rather be understood as an active action 
like it is being done within the endogenous loading process of the cell. Because of the 
small size of exosomes, both exo- and endogenous loading methods are very 
challenging and the capacity of the EVs is limited to their volume. 
For exogenous loading, there are mainly three approaches: loading after formation of 
pores, loading without formation of pores and loading with the help of an osmotic 
gradient. The formation of pores in the vesicles is usually done with detergents like 
saponin to permeabilize the membrane. Mechanical methods for pore formation are 
electroporation, freez- and thaw-cycles and sonication. When EVs are incubated with 
the drug without formation of pores, drugs are sometimes modified with cholesterol 
or other conjugations like ubiquitination to increase their localization to exosomes 
(Stremersch et al., 2016, Sterzenbach et al., 2017). To permeabilize EVs with the help 
of osmosis, the vesicles are subjected to a hypotonic solution which induces a swelling 
and therefore a slight disruption of the membrane. This way, molecules can diffuse 
into the vesicles (Fuhrmann et al., 2015). 
For the endogenous loading, cells are transfected with the gene of the therapeutic 
protein or RNA and a proportion of the molecule localizes to the EVs. The conjugation 
and modification of the protein-encoding gene by for example, a C1C2-domain of a 
vesicle membrane located protein lactadherin (Zeelenberg et al., 2008) or the 
exosomal membrane protein Lamp2b (Alvarez-Erviti et al., 2011) can enhance the 
amount in the vesicles. Fusion of the cargo-protein to a vesicle membrane protein 
results in a high recovery within the exosomes but leads to an anchoring of the 
protein to the membrane, which might in some cases inhibit the enzymatic activity of 
the protein. 
For all methods used it is crucial to perform appropriate controls. For instance, 




and subsequent loading but by now it is known that molecules tend to aggregate after 
the application of an electric field (Luan et al., 2017). Therefore, these protein 
aggregates properties might resemble vesicular properties in centrifugation steps or 
when applied to size exclusion chromatography columns and thus might lead to false 
positive results. 
1.3.3 Exosome application and distribution  
Although exosomes reached the clinical application for diagnostic purposes, for 
example in the diagnosis of lung cancer (Sheridan, 2016) and the number of clinical 
trials almost doubled in 2017, there were only 2 trials on EVs for therapeutical 
application (Gimona et al., 2017). There are still major challenges that have to be 
resolved before they can be applied on regular basis as therapeutics. The production 
and application of biopharmaceuticals is more difficult than of a single chemical 
molecule. In contrast, the synthesis of biologicals such as proteins or vesicles is more 
complex and the delivery is not as straightforward. Other liabilities are the 
temperature and moisture the product needs to sustain during storage and inside the 
body (Mitragotri et al., 2014). In case of exosomes or EVs, the screening for a stable 
product with defined content and properties represent major hurdles that have to be 
overcome. 
At the current state of science it is believed that exosomes can be stored in their 
biological matrix following a crude purification by which contaminations are removed 
(Lener et al., 2015). It is also assumed that exosomes are less effected by freeze- and 
thaw-cycles than proteins (Lener et al., 2015). 
EVs have been applied in animal experiments by numerous administration routes: 
orally (Munagala et al., 2016), intravenously (i.v.) (Takahashi et al., 2013)and 
intranasally (Zhuang et al., 2011). EVs behave in vivo similar to liposomes of small size 
and with negative surface charge (van der Meel et al., 2014). Intravenously applied 
liposomes result in a better overall tissue distribution when the circulation time is 
extended. Nevertheless,  the main organs for the uptake remain liver and spleen (van 




exogenous origin of the obtained EVs will have substantial influence on their 
distribution within an organism. For i.v. applied not modified exosomes an uptake in 
the liver and spleen could be proven in small animal experiments just as for 
liposomes (Tian et al., 2014). For orally administered vesicles a better overall 
distribution and a reduced accumulation in the liver than for i.v. applied EVs could be 
proven. The uptake of the orally administered vesicles and their correct delivery 
could be proven by the observed anti-tumorigenic effect (Munagala et al., 2016). 
The intraventricular and intranasal applications are a more direct routes to the CSF. 
By this route, the BBB and the BCSFB can be bypassed and the local concentration in 
the brain is increased in comparison to a systemic application. In other experiments 
with intranasally applied proteins a passage of 0.001 % of the totally applied protein 
could be detected in the CSF (Wolf et al., 2012). In the case of intranasal application, 
the drug is able to be taken up through the mucosa of the nose, passes the olfactory 
bulb and finally reaches the cerebrospinal fluid.  
1.4 Model diseases suitable for the screening of exosomal transport vehicles  
In this project, two neuropediatric diseases were considered as suitable for the 
screening of FRα-presenting vesicles as drug delivery vehicles to the CNS.  
1.4.1 Late infantile neuronal ceroid lipofuscinosis 
Neuronal ceroid lipofuscinosis (NCL) is a group of rare diseases that belong to the 
childhood dementias. There are at least 13 genetic defects that are associated with 
distinct types of NCLs sharing characteristic lysosomal storage (Rakheja and Bennett, 
2018). In the past, subgroups were categorized according to their clinical appearance. 
Late infantile NCL, LINCL has an onset with 2-4 years. All NCL diseases present with 
similar symptoms like early loss of vision, progressive neuronal degradation and 
motor dysfunction (Bennett and Rakheja, 2013). The patients have a significantly 
reduced life expectancy and are strongly impaired by the neuronal loss. This fatal 
course of disease with no curative treatment generates a pressing need for new 




The NCL disorders share the accumulation of lipofuscin in the cells resulting from the 
impaired lysosomal function. Mutations in the gene CLN2 encoding tripeptidyl-
peptidase I (TPPI) lead to the loss of the lysosomal peptidase activity and the clinical 
manifestation of LINCL (Wisniewski et al., 2001). While for most forms of NCL no 
curative treatment is available, for CLN1, CLN2, CLN10 and CLN13 (Neverman et al., 
2015) an enzyme replacement therapy (ERT) is feasible and under investigation in 
clinical trials, after promising results in animal experiments (Wiseman et al., 2017, 
Chang et al., 2008). 
The mouse model for LINCL was established by disruption of the murine TPPI-
encoding gene by a point mutation (Sleat et al., 2004). These mice have a survival of 
138 d during which 90 % of the animals die. These mice have a similar phenotype as 
described in human patients: they are born healthy or apparently healthy and then 
develop tremor, ataxia and show symptoms of neurodegeneration. These mice could 
be treated by an ERT and disease progression slowed down (Chang et al., 2008). The 
ERT was administered by intraventricular injection by implantation of an osmotic 
pump into 60 days old mice. This pump continuously injected 100 µl TPPI for 1 month 
in a concentration of 1 mg/ml. 
TPPI is a soluble lysosomal protein (Bennett and Rakheja, 2013). The precursor of 
TPPI appears with a size of 66 kDa (Guhaniyogi et al., 2009). The mature form has a 
size of 48 kDa (Golabek et al., 2004). The signal peptide in the precursor directs the 
protein to the endoplasmic reticulum for glycosylation. The mature form is formed by 
catalytic processing within the cell in the lysosome at low pH (Guhaniyogi et al., 
2009). 
1.4.2 Biopterin Disorders 
Biopterin is an essential cofactor in the synthesis of dopamine, serotonin, tyrosine 





Figure 1.4: Metabolism of biopterin adopted and modified from Clot et al.. 
Defects in the biopterin metabolism originate from dysfunctions in the synthesis reactions by 
defects in the Guanosine Triphosphate Cyclohydrolase I (GTPCH), the Sepiapterin Reductase 
(SR) or the target protein in this project 6-Pyrovyoltetrahydrobiopterin-Synthase (PTPS) or 
by dysfunctional regeneration of tetrahydropterin (BH4) from dihydropterin (BH2) by the 
enzyme Dihydropteridine reductase (DHPR). This leads to very severe metabolic disorders 
among others by imbalances of the amino acids phenylalanine (Phe), Tyrosine (Tyr) and 
Tryptophan (Trp) or a lack of dopamine and serotonin (Clot et al., 2009). 
A biopterin disorder is either caused by a defect in the synthesis or a defect in the 
regeneration of the cofactor, for instance by dysfunction of the enzyme 
dihydropteridine reductase (DHPR). The synthesis of biopterin is made up by three 
enzymatic steps as visible in figure 1.4. Defects in the gene encoding the second 
enzyme the 6-Pyrovyoltetrahydrobiopterin-Synthase (PTPS) are the most common 
mutations resulting in tetrahydrobiopterin deficiency (Niu, 2011). Biopterin 
disorders are nowadays identified by newborn screenings, presenting with elevated 
phenylalanine (Phe) concentrations in the blood (Mascaro et al., 2016). In the past, 
prior to the introduction of newborn screenings, the disorder manifested as a 
neurological disorder with symptoms similar to Parkinson diseases (Liu et al., 2008). 




are substituted with biopterin, 5-hydroxytryptophan and L-Dopa. The long-term 
treatment of these patients is challenging since medication must regularly be adapted 
according to the results of the CSF-analysis obtained by lumbar punctuation (Niu, 
2011). Despite an early therapy onset there are affected children with reduced IQ 
score and patients that suffer from dyskinesia (Dudešek et al., 2001). 
The enzyme is a small protein of 16.9 kDa with 148 amino acids. Mammalian PTPS is 
functional in a homohexameric form (Thöny, 2006). It is ubiquitously present (Thöny, 
2006) and depends on the presence of magnesium (Bürgisser et al., 1995). The 
measurement of the PTPS-activity is difficult since the substrate 7,8-dihydroneopterin 
triphosphate needs to be synthesized in situ and the reaction is therefore based on a 
multiple step enzyme reaction. Additionally, the third enzyme of the biopterin 
biosynthetic pathway, sepiapterin reductase, needs to be present to convert the 
highly unstable 6-pyruvoyltetrahydropterin to biopterin. Biopterin is finally 
measured by HPLC with fluorescence detection of the fluorescent product (Blau et al., 
2008). 
Mice lacking PTPS-activity (pts-/- mice) have a very severe phenotype and die 
perinatal or few hours up to some days after birth (Sumi-Ichinose et al., 2001, Elzaouk 
et al., 2003). These animals can be rescued by substitution therapy as described for 
human patients with biopterin, 5-hydroxytryptophan and L-Dopa, however with ten-
fold higher doses needed. The most striking on their phenotype is the strong growth 
retardation, the pts-/- mice have only one-third of the normal body weight (BW) at 
maturation with 7.8±1.5 g in comparison to 23.1±2.4 g of a healthy mouse at that age 
(Elzaouk et al., 2003). This very severe phenotype and the high amount of 
substitution result from the higher PTPS-enzyme activity. The murine PTPS is 
approximately ten times more active than the human one (Elzaouk et al., 2003). The 
treated pts-/- mice have more symptoms like hypersalivation, reduced rate of activity 




1.4.3 FRα-conjugated nanoparticles 
Another therapeutic approach will be to analyze the performance of FRα-conjugated 
artificial nanoparticles (NPs) that will be loaded with sepiapterin. These particles are 
designed in Technion by a cooperating group (Prof Sosnik’s group). Originally, it was 
planned to load biopterin to these nanoparticles but because of its low stability, 
sepiapterin was chosen for the nanoparticles. Additionally, FRα was conjugated by 
functionalized carboxymethyl- and amine-groups to the surface of the NPs. Since 
sepiapterin is the product of the reaction of PTPS, this substitution should have a 
similar beneficial effect as the substitution with PTPS. Providing the enzyme itself to 
the cells might have a more consistent effect on the biopterin metabolism. The effect 
is highly depending on the uptake and distribution of the particles just as the amount 





1.5 Aims of the study 
Because of the central role of FRα in the transport of folates into the brain and its role 
in many malignancies, it is an attractive candidate for the conjugation to drug 
transport vehicles from biological as well as synthetic origin. Nanoparticles are of 
great interest because of their multimodal properties. Biological NPs like exosomes 
might have even more advantages because of their biocompatibility, but their 
production, evaluation and maintenance are at the moment more challenging.  
The project can be divided into three main parts: 
1 .  Production and characterization of vesicles for the future therapeutic 
application  
a. Purification of EVs from human cell culture line in a high scale with and 
without the FRα-conjugation  
b. Comparison of the most common isolation procedure with the 
established purification method 
c. Full characterization of the EV preparation according to the guideline of 
the International Society of Extracellular Vesicles (ISEV) 
2 .  Introduction of therapeutic cargo to the EVs 
a. Exogenous loading and quantification of the charged drug enzyme 
b. Endogenous loading and quantification of the charged drug enzyme 
3 .  Investigation of the biological performance of the designed EVs 
a. Analysis of the uptake of the prepared EVs outside of the organism 
b. Analysis of the biodistribution within mice by screening of the organs 
c. Evaluation of the therapeutic capacity in an appropriate mouse model 
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2 Materials and methods 
2.1 Materials 
Table 1: List of materials 
Materials Company 
Amicon ultrafiltration unit 10, 50, 100 K Merck KGaA 
dialysis tube, Zellutrans 6,0 Carl Roth GmbH + Co. KG 
Cuvette, 4 mm Bio Rad Laboratories GmbH 
glas cloning rings Hilgenberg GmbH 
HisTrapTM FF crude column  GE Healthcare 
IRDye800 CW LI-COR Biotechnology GmbH 
Microplate, 96-well, black flat bottom Greiner Bio-One GmbH 
Microplate, 96-well, flat bottom  Greiner Bio-One GmbH 
MINIPERM® Sarstedt AG & Co. KG 
monolithic column, CIMmultusTM IDA-Cu  BIA Seperations d.o.o., Slovenia 
monolithic column, CIMmultusTM QA BIA Seperations d.o.o., Slovenia 
Nitrocellulose blotting membrane AmershamTM 
Protran® 0,45 µm AmershamTM 
tubes for flow cytometry, 5 ml Falcon 
Vivaspin 10 000, 30 000 MWCO Sartorius AG 
24-well plates Sarstedt AG & Co. KG 
Table 2: List of specific instruments 
Instruments Company 
Centrifuge, 5417R Eppendorf AG 
Centrifuge, 5424 Eppendorf AG 
Centrifuge, Mikro 200R, Rotor 2424-B Andreas Hettich GmbH & Co. KG 
Centrifuge, mini, FugeOne® Starlab GmbH 
Centrifuge, mini, Sprout Biozym Scientific GmbH 
Centrifuge, Universal 320, rotor 1619 Andreas Hettich GmbH & Co. KG 
FACS Canto II Beckham Coulter GmbH 
Gene Pulser Xcell  Bio Rad Laboratories GmbH 
Microplate reader, Bio Tek Synergy Mx Bio Tek® Instruments 
Nanosight LM10-HS Malvern Instruments 
Optix 2 Fa. ART 
Rota Rod TSE Systems GmbH 
Ultracentrifuge, SW 28 rotor Laborgeräte Beranek GmbH 
Luminescent image reader, LAS-400 mini Fujifilm 
MOUSE E MOTION INFRA-E-MOTION, Hamburg 
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ÄKTA-system  AmershamTM 
Table 3: List of mammalian cell lines 
Cell 
line 
Cell type obtained 
from  
HEK293 human embryonic kidney 
cells 
ATCC 
K562 human myelogenous 
leukemia blood cells 
ATCC 
BN16 Brown Norway rat 
choriocarcinoma cells/ 
rat yolk sac carcinoma cells 
Cooperation 
partner:       
AG Hammes 
MDC Berlin 
Table 4: List of chemicals 
Material Manufacturer 
2-propanol Merck KGaA 
acrylamide solution, 30 % with 0.8 % 
bisacrylamide Carl Roth GmbH + Co. KG 
Agarose Bioline GmbH 
Ala-Ala-Phe-7-amido-4-methylcoumarin Bachem 
ammonium persulfate (APS) Serva Electrophoresis GmbH 
ampicillin sodium salt Sigma Aldrich 
BCA assay reagent A Interchim 
BCA assay reagent B Interchim 
Biopterin (11.203) Schricks laboratories 
bovine serum albumin (BSA), Fraktion V Carl Roth GmbH + Co. KG 
bromphenol blue Merck KGaA 
BSA standard solution 2mg/ml Interchim 
Carbon grid Formvar/carbon FCF300-Cu            Agar-Scientific, Stansted UK 
CoCl2 Sigma Aldrich 
dimethyl sulfoxide Serva Electrophoresis GmbH 
ethanol Merck KGaA 
ethylenediamine tetraacetic acid (EDTA) Carl Roth GmbH + Co. KG 
eye salve Augen- und Nasensalbe Bepanthen® 
fetal bovine serum (FBS) PAA Laboratories GmbH 
Geltrex Gibco 
GeneRulerTM, DNA ladder mix Fermentas Life Science 
GlutaMAXTM(100x) Gibco 
glycerol, anhydrous Applichem 
HCl Merck KGaA 
HEPES-buffer Carl Roth GmbH + Co. KG 
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KH2PO4 Carl Roth GmbH + Co. KG 
LB-Agar (Luria/Miller), powdered Carl Roth GmbH + Co. KG 
L-glutamine solution Sigma Aldrich 
Lumi-Light Plus Western Blotting substrate Roche Deutschland Holding 
GmbH 
lysogenic broth (LB)-medium, powdered Carl Roth GmbH + Co. KG 
mCling-Atto647 Synaptic Systems GmbH 
methanol J.T. Baker 
milk powder Carl Roth GmbH + Co. KG 
N,N,N',N'-Tetramethylethan-1,2-diamin 
(TEMED) Carl Roth GmbH + Co. KG 
Na2PO4 Carl Roth GmbH + Co. KG 
NaCl Carl Roth GmbH + Co. KG 
NaOH Carl Roth GmbH + Co. KG 
PageRulerTM Prestained Protein Ladder Thermo Fisher Scientific 
paraformaldehyde sulfonic fluoride (PMSF) Applichem 
PBS (Dulbecco's PBS) for cell culture Biowest 
Ponceau-S solution Sigma Aldrich 
Saponin Carl Roth GmbH + Co. KG 
sodium dodecyl sulfate (SDS), 20 % solution Carl Roth GmbH + Co. KG 
ß-mercaptoethanol Sigma Aldrich 
sucrose Riedel-de Haën 
Triton® X 100 Carl Roth GmbH + Co. KG 
Tryptan blue, 0.5 % (w/v) in physiological 
saline Biochrom GmbH 
Tween® 20 Merck KGaA 
 
Table 5: List of enzymes and kits 
Enzyme/Kit Company 
BamHI New England BioLabs® Inc. 
BigDye Terminator v3.1 Cycle Sequencing Kit Thermo Fisher Scientific 
Effectene Transfection Reagent Qiagen 
HindIII New England BioLabs® Inc. 
Lumi-Light Western Blot substrate Thermo Fisher Scientific 
NheI New England BioLabs® Inc. 
NotI New England BioLabs® Inc. 
NucleoBond® Xtra plasmid purification Macherey-Nagel 
NucleoType Mouse PCR Macherey-Nagel 
PageRuler Plus Prestained Protein Ladder Thermo Fisher Scientific 
PageRuler Prestained Protein Ladder Thermo Fisher Scientific 
PierceTM BCA Protein Assay Kit Pierce 
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SacI New England BioLabs® Inc. 
ScaI New England BioLabs® Inc. 
Trypsin/EDTA solution, 0.05 %/0.02 % (w/v) Biochrom GmbH 
 
Table 6: List of bacterial strains 
Name Cell type Characteristics obtained from  
Top Ten 
Escherichia 





coli high-level expression strain Qiagen 
 
Table 7: List of buffer and media as well as their recipes  
Media/Buffer Additives/Recipe Company 







5 % (v/v) FCS                   
1 % (v/v) L-glutamine 
Merck KGaA 
HEK293            
serumfree 
conditions 
293 SFMII  1 % glutamax Thermo Fisher 
Scientific 
K562                         
culture 
medium 





137 mM NaCl               
2.7 mM KCl 
 
  
10 mM Na2HPO4 
 
  





PBS-T buffer  
 
PBS 





240 mM NaCl                      








240 mM NaCl                       
20 mM KH2PO4 
 
  





buffer A     
(IEC) 
 
20 M Tris                               
pH 8.0 
 
buffer B     
(IEC) 
 
20 M Tris                             







 50 mM NaH2PO4 
300 mM NaCl 
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buffer 10 mM Imidazole 
0.05 % Tween 20 
pH 8.0 
flow 
cytometry                          
buffer 
 





0.5 – 2.5 sucrose 
HEPES-buffer 
 
4x SDS-PAGE                       
sample buffer 
 
160 mM Tris/HCl pH 6.8 
8 % (v/v) SDS 
10 % ß-mercaptoethanol 
0.01 g bromphenolblue 
20 % Glycerol 
 




25 mM Tris                 
192 mM Glycin              
0.1 % (w/v) SDS     
 




25 mM Tris                         
160 mM Glycin                            
20 % (v/v) MeOH 
 
 
Table 8: List of primary antibodies 
Antibody  Host Dilution Company 
anti-AIP/Alix rabbit  1:500 MerckMillipore                                 
Cat# ABC40                                       
Lot# 2867560 
anti-flotillin2 mouse  1:1000 BD Biosciences                                  
Cat# 610383                                      
Lot# 7006854 
anti-FRα (MOV18) mouse  1:400 Enzo Life Sciences                             
Cat# ALX-804-439                           
Lot# 12151407 
anti-FRα (NCL) mouse  1:2000 Leica Biosystems                   
Cat#NCL-L-FRα Clone BN3.2                
Lot#L159505    
anti-PTPS rabbit  1:2000 Thermo Scientific                         
Cat#PA5-22121                      
Lot#QH2071081D    
anti-TOM20 rabbit  1:1000 Santa Cruz                                             
Cat# sc-11415   
anti-TPPI  mouse  1:1000 Sigma Aldrich           
Cat#WH00001200              
Lot#06097-3B1 
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Table 9: List of secondary antibodies 
Antibody  Host Dilution Company 
anti-mouse IgG               
Alexa Fluor532 
conjugated 
goat 1:800 life technologies                            
Cat#A11002        
anti-mouse IgG         
HRP-conjugated  
donkey 1:10 000 Jackson ImmunoResearch               
Cat#715-035-151 
anti-rabbit IgG              
HRP-conjugated 
goat 1:5000 Jackson ImmunoResearch              
Cat#711-605-152 
 
Table 10: List of primers 





















Table 11: List of plasmids 
Plasmid Characteristics Reference 
pBluescript II KS+ 
 ampicillin-sensitiv, T7 




pUC57 backbone, high 






pREP4 repressor, lacIq, 
F-factor episome, 6his-
tag, human PTPS Qiagen 
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Table 12: List of software 
Software Distributor 
Nanosight Tracking 
Analysis 2.3  
Malvern Instrument 




Flowing 2.5.1 Perttu Terho; Cell Imaging Core of the Turku Centre for 
Biotechnology 
UnicornTM 5.31 GE Healthcare 
2.2 Methods 
2.2.1 EV sample preparation and cell culturing 
Preparation of supernatant for EV-isolation 
Initially, the production of eukaryotic EVs was scaled up by the introduction of a 
production unit. In this project the MINIPERM® bioreactor from Sarstedt was used. 
There are by now more systems available, for example hollow-fiber bioreactors. The 
main benefit of a bioreactor is the high cell density that leads to a highly concentrated 
starting material. In the MINIPERM® bioreactor 107 cells per ml can be applied. 35 ml 
are in the production unit while 350 ml are in the supply unit. The supply unit 
contains medium supplemented with fetal calf serum (FCS). FCS contains fetal 
vesicles; usually it is recommended to remove the particles by ultracentrifugation. In 
the bioreactor, the cells are separated by a dialysis membrane from the supply unit 
and big particles are not able to pass. This way the cells are kept in optimum 
conditions, while contaminations from external EVs are prevented. All samples were 
centrifuged for 30 min at 4°C with 4500 rpm to remove cell debris and filtered with a 
0.4 µm membrane, then samples were either directly subjected to the isolation 
protocol or stored at -20°C. 
For HEK293 cells stably expressing FRα were cultured in 293 SFMII with 1 % 
glutamax in the production unit. In the supply unit was filled with DMEM with high 
glucose and 5 % of FCS. When K562 were used for EV preparation in the bioreactor 
the cells were cultured in RPMI medium.  
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2.2.2 Fast performance liquid chromatography 
For all protocols run with the fast performance liquid chromatography (FPLC)-system 
the buffers were filtered through 0.22 µm and degassed. The FPLC was run at 10°C.  
Detailed protocol for SEC 
The used material for size exclusion chromatography (SEC) is CaptoTM Core 700 
(CC700). CC700 beads have an inactive shell while the surface in the pores of the 
beads is modified with octylamine ligands. Particles with a size smaller than 700 kDa 
are able to penetrate the beads and bind to the material because of the positive charge 
and the hydrophobic nature of the ligand. For this reason, this column functions as a 
scavenger column. The beads are very pressure-sensitive; this is why columns with 
great bed diameter need to be used to reduce the backpressure. When column 
packing is performed according to the supplier’s protocol (GE Healthcare), the 
working pressure should not exceed 80 % of the packing pressure. In this case, it 
leveled at 0.2 MPa. For this project, best experiences were made with the empty 
column HiScaleTM 16/20 (GE Healthcare) with a diameter of 16 mm and a tube height 
of 200 mm. 1 ml of CC700 material is able to bind 13 mg of contaminating material 
according to the supplier. On average, the supernatant had a concentration of 
2 mg/ml total protein. The samples from cells with empty vector had lower total 
protein concentrations. With a typical packing volume of 20 ml, a total of 260 mg 
protein could be applied in about 130 ml of supernatant. To be able to apply such high 
sample volume, a 50 ml sample loop and an additional pump were used. 
Because of the huge amount of retained proteins in the column beads, the column 
should be immediately regenerated before its storage. For all experiments described 
in this project, the SEC-column was regenerated by a harsh washing protocol with 
1 m NaOH in 30 % isopropanol (v/v). 
Detailed protocol for IMAC 
For immobilized metal affinity chromatography (IMAC), buffer A was 140 mM NaCl 
with 20 mM phosphate at pH 7.4, and buffer B contained additionally 500 mM 
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imidazole for elution. The buffers should have pH higher than 6 to remain histidine 
sidechains in the deprotonated form. Histidine has a pKa of 6. To reduce unspecific 
binding, the SEC-product was supplemented with 8 % of buffer B, resulting in a 
concentration of 40 mM imidazole. The whole product is applied with the 50 ml 
sample loop in several steps to the column. The column is washed with 20 column 
volumes (CVs) of buffer A with 8 % buffer B. The stepwise gradient is split in three 
steps with 20, 50 and 100 % buffer B, with corresponding concentrations of 100, 250 
and 500 mM imidazole. Each gradient step is 5 CV. Fractions of 2 ml were collected. 
This column can be regenerated by washing with 1 M NaOH with 1 M NaCl. 
Precipitated lipids should be removed with 30 % isopropanol. The column needs to 
be recharged with Cu2+ after each cleaning procedure. 
Detailed protocol for IEC 
For the ion exchange chromatography (IEC) 20 mM Tris-buffer, pH 8.03 was used, 
with additionally 1 M NaCl for elution in buffer B. A stepwise elution gradient with 
steps of 5 CVs with a flow rate of 2 ml/min, beginning with 20, 50 and in the end 
100 % of buffer B were applied. 
Design of the eukaryotic expression vector XLone-GAP43PTPS 
XLone-GAP43PTPS was designed for analysis of the endogenous loading of a 
membrane-targeted enzyme. The suggestion to use GAP43 for this purpose was given 
by Professor Rizzoli (3rd Committee Meeting, 20th Nov. 2017). GAP43 is a nervous-
tissue specific growth-associated protein with an originally observed size of 43 kDa 
(GAP43) (Karns et al., 1987). The first 20 amino acids include a palmitoylation 
sequence and result in membrane localization. 
The sequence was provided by Professor Rizzoli’s group and was introduced to the 
vector pBluescript (pBS) by PCR amplification with the primers Pr_GAP43-for and 
Pr_GAP43-rev. The sequence of the pts-gene (Gene ID: 5805) encoding PTPS was 
amplified by PCR, resulting in GAP43-pBS. The start-codon was removed and a 
restriction site for SacI and introduced with the primer Pr_PTPS w/o ATG SacI-for and 
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Pr_PTPS w/o ATG SacI-rev. GAP43-pBS was digested with ScaI and SacI, PTPS was 
digested by SacI and NotI and  ligation performed. In the end the product GAP43-PTPS 
was extracted from the vector pBS by digestion with the enzymes NheI and NotI and 
introduced to the vector XLone for the plasmid XLone-GAP43-PTPS. The sequence 
was verified by sequencing.  
2.2.3 EV-Preparation by DC 
In the first step, big particles and debris were removed by slow centrifugation for 
15 min at 1 500 x g and 4°C. In the second step, smaller particles are removed by a 
centrifugation at 10 000 x g for 45 min at 4°C and at last, the EVs are pelleted by ultra-
centrifugation at 100 000 x g for 2.5 h at 4°C. 
2.3 Protein biochemistry 
2.3.1 Purification of PTPS from E. coli recombinant production strain 
Human PTPS was prepared in bacterial strain to simplify the purification and obtain 
high yields. For this purpose, the M15 strain and the QE9 plasmid from Qiagen were 
used. The M15 strain contains the pREP4 plasmid which confers a kanamycin 
resistance and constitutively expresses the lac repressor protein. The sequence of the 
pts-gene (Gene ID: 5805) was amplified by PCR. The start-codon was removed, the 
sequence for a 6his-tag inserted as well as restriction sites for the enzyme BamHI, 
N-terminally, and HindIII, C-terminally, added with the primer Pr_PTPS_BamHI and 
Pr_PTPS_HindIII. The PCR product was cloned into the pQE-9 vector after digestion 
with BamHI and HindIII. After transformation in Top Ten Escherichia coli strain cells, 
DNA was extracted with the kit NucleoBond® Xtra plasmid purification. The sequence 
of the product was confirmed by Sanger sequencing with the primer Pr_QE-Seq_for 
and Pr_QE-Seq_rev with the kit BigDye Terminator v3.1 Cycle Sequencing kit. The 
final plasmid was transformed to the expression strain M15. 
For protein expression, a starter culture of the generated M15 strain in LB-medium 
with kanamycin and ampicillin was grown over night. Then, a main culture with 25 ml 
was inoculated 1:25 and grown to optical density of 0.4-0.6 at 37°C. Induction with 
1 mM IPTG was performed. The culture was left at 37°C for 4-5  to allow protein 
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expression to take place. Then the cells were harvested by centrifugation at 4000 rpm 
for 20 min at 4°C. The pellet was suspended in 5 ml of protein extraction buffer and 
frozen in liquid nitrogen. After thawing, the sample was sonicated with maximal 
power for 6 times 10 s. Cell debris was removed by centrifugation with 10 000 rpm 
for 30 min at 4°C.  
The supernatant was then applied to a HisTrapTM FF crude column and the bound 
protein was eluted with stepwise increasing imidazole concentrations of 40, 250 and 
500 mM. PTPS was eluted in fractions at 250 and 500 mM of imidazole, respectively. 
The largest amount of PTPS was recovered at the highest imidazole concentration. 
PTPS activity assay was confirmed by Tanja Scherer according to an established 
protocol (Bonafé et al., 2001). 
2.3.2 Purification of TPPI 
The purification of TPPI was performed as previously reported with minor 
modifications (Pal et al., 2008). In contrast to the published protocol a step gradient 
with three steps with 100, 250 and 500 mM imidazole was applied. The major amount 
of TPPI was eluted in the first step with 100 mM imidazole, the fractions of the peak 
were pooled and imidazole removed by concentrating and washing in an 
ultrafiltration unit. 
TPPI-activity assay 
TPPI activity can be measured by an internally not fluorescent substrate, Ala-Ala-Phe-
7-amido-4-methylcoumarin. The peptidase is able to cleave Ala-Ala-Phe and thus the 
internal quencher from the fluorophore. 
The reaction is performed in a buffer of 100 mM sodium acetate, 10 mM EDTA and 
0.02 % sodium azide. 10 µl of the sample are acidified with sodium fumarate to a pH 
of 3.5. Then the samples are left at RT for 1 h to allow TPPI to autoactivate to its 
mature form. The substrate is taken up in a concentration of 30 mM in 10 µl of 
substrate buffer, 100 mM sodium acetate, 10 mM EDTA, 0.02 % sodium azide. 40 µl of 
the reaction buffer, 0.2 % bovine serum albumin (BSA), 0.9 % (w/v) NaCl, 0.02 % 
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sodium azide are preloaded in a black 96-well plate for fluorescent assays. At last, 
10 µl of sample are added. In case of high concentrated TPPI, the sample can be 
diluted in 0.2 % BSA, 0.9 % NaCl (w/v) and 0.02 % sodium azide. Protease inhibitors 
are given to the reaction with following concentrations: pepstatin A (8.34 mM) and 
E64 (24 mM). The plate is placed at 37°C, mildly shacking and protected from light. 
Then the reaction is stopped with 150 µl per well carbonate glycine buffer at pH 9.7. A 
calibration curve with 7-amido-4-methyl-coumarin is prepared in water. It is 
preloaded in duplicates in a range of 285-1 472 nM.  
2.3.3 BCA assay 
Protein quantification was performed with a calorimetric reaction taking place with 
bicinchoninic acid (BCA). The color change with proteins can be detected at 562 nm 
with a photometer. A BCA-kit from Pierce was applied. A standard curve was 
prepared from BSA standard solution of 2 mg/ml and applied in duplicates to a 
transparent 96-well plate in concentrations from 0-30 µg per well. Samples were 
added in volumes of 25 µl and in duplicates as well. In each well 200 µl of reagent mix 
A+B (1:50) was added. Reactions were incubated for 30 min at 37°C and then read out 
with a microplate reader.  
2.3.4 SDS-PAGE and Western Blot analysis 
In order to analyze the protein composition of the EV-preparation or to detect the 
cargo enzyme, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
was performed followed by Western Blot analysis. SDS is a strong detergent binding 
to proteins in a ratio of 1.4:1 g and resulting in a negative charge of the protein.  
In this project, discontinuous gel electrophoretic systems with a 10 and a 15 % 
polyacrylamide gel were applied. The gels were prepared according to the recipe in 
table 13. Protein samples were dissolved to the final protein amount and 4x SDS-
sample buffer was added. The samples were boiled at 95°C for at least 10 min. and 
then samples were applied to the wells in the gel with a Hamilton syringes. A 
prestained protein ladder was used. The electrophoresis was run at low current with 
20 mA until the sample dye left the gel. Blotting was performed to a nitrocellulose 
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membrane placed in between a Whatman filter paper sandwich within a semi-dry 
blotting system. This step was performed with 1 mA per 1 cm2 of membrane area for 
90 min. To reduce unspecific binding of the antibody, the blot was placed for 1 h in 
5 % (w/v) milk powder in PBS-T. Antibodies were diluted in the same buffer. The 
primary antibody was applied overnight at 4°C, the secondary for 1 h at RT. In 
between, the blot was washed three times for 5 min with PBS-T. The peroxidase-
conjugated secondary antibody was visualized with Lumi-Light Plus Western Blotting 
substrate in the Luminescent image reader. 
Table 13: Preparation of 10 and 15 % discontinuous polyacrylamide gels 
Compound Stacking gel 
10 %     
resolving gel 
15 %     
resolving gel 
H2O 1.4 ml 1.9 ml 1.1 ml 
30 % acrylamide 
solution 330 µl 1.7 ml 2.5 ml 
1.0 M Tris, pH 6.8 250 µl / / 
1.5 M Tris, pH 8.8 / 1.3 ml 1.3 ml 
10 % SDS 20 µl 50 µl 50 µl 
10 % APS 20 µl 50 µl 50 µl 
TEMED 2 µl 2 µl 2 µl 
final volume 2 ml 5 ml 5 ml 
 
2.4 Experimental methods 
2.4.1 Analysis of density by centrifugation on a sucrose gradient 
The vesicle samples were prepared as indicated either by SEC followed by IMAC or by 
DC. For preparation of a gradient, a sucrose stock solution was dissolved to 2.5 M in 
HEPES. The other sucrose solutions were prepared according to table 14. The 
gradient was carefully layered from the bottom up, beginning with 2.25, 2.0, 1.75, 1.5, 
1.25, 1.0, 0.75 and 0.5 mM sucrose. The sample was added in 0.25 mM sucrose with 
the same volume. From each EV preparation, 700 µg were applied onto the sucrose 
gradient. Then, ultracentrifugation was performed for 16 h at 4°C in a SW28 tube 
rotor with 26 000 rpm which corresponds to 100 000 x g. The fractions were regained 
in the same manner and of each fraction samples subjected to analysis by Western 
Blotting.  
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Table 14: Preparation of sucrose solutions for sucrose gradient centrifugation. 
sucrose 
concentration [M] 
2.5 M                  
stock solution [ml] 
HEPES                  
[ml] 
density                      
[g/cm3] 
2.25 13.5 1.5 1.29 
2 12 3 1.25 
1.75 10.5 4.5 1.23 
1.5 9 6 1.19 
1.25 7.5 7.5 1.16 
1 6 9 1.12 
0.75 4.5 10.5 1.09 
0.5 3 12 1.06 
0.25 1.5 13.5 1.03 
2.4.2 Nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) is a new method first sold by NanoSight Ltd in 
2003. It composed of a light microscope with an illumination unit, enabling a camera 
to record the movement of nanoparticles. With this video file along with the 
temperature and viscosity of the solution, the size of particles can be determined 
based on the formula of Brownian motion.  
The NTA instrument, NanoSight LM10-HS, used in this thesis was provided by the 
group of Professor Schneider (MPI Experimental Medicine, Göttingen). The NanoSight 
was equipped with a high sensitivity CMOS camera, a LM14 viewing unit with a 
532 nm laser and a fluorescence filter.  
For analysis of particle concentration and the size distribution of the raw, 
SEC-prepared sample or the EV preparations, a sample concentration needed to be 
diluted to 2x108-109 particles per ml. To be more precise, the raw sample from cell 
culture was usually diluted 1: 10 000, the SEC-product 1:1 000and the EV-fractions 
from the FPLC-purification 1:10. The EV sample from the DC protocol was diluted 1: 
10 000 with PBS. Approximately 0.5 ml sample were applied with a syringe to the 
sample chamber. Triplicates of 30 sec videos were recorded. Analysis was 
implemented by Nanosight Tracking program Analysis 2.3. The mean and mode 
particle size, sample concentration and a graph of the size distribution were taken for 
analysis.  
Materials and methods 
31 
 
Utilizing a fluorescence filter, an indirect labeling protocol could be performed. 
Therefore, the sample particle concentration was adapted to 1010 particles per ml. 
1.25 µl of primary antibody, MOV18 (Enzo Life Sciences, USA) were added and the 
samples were placed at 4 °C for 1 h with mild agitation to allow binding to form. 
Access primary antibody was removed by washing with PBS in a small ultrafiltration 
unit (50 K) with 3500 rcf with 5x 500 µl. Then, the secondary conjugated antibody, 
AlexaFluor532 was added in 1.25 µl and again incubated at 4°C for 30 min. By 
previous experiments it was shown that there is no need to perform a second wash 
for removal of secondary antibody. The fluorescent labeled samples were applied to 
the NTA without further dilution.  
Photo bleaching is a major challenge for working with fluorescent particles in NTA 
because the time frame of a recording takes at least 5 s. For this reason, analysis must 
be performed with a pump under flow to supply the chamber constantly with fresh 
sample. The flow rate was as recommended by the supplier for LM10-14 for 
fluorescent measurement 80 (Malvern Instruments). According to my experience, it is 
advisable to use the pump in general to be able to analyze an extended volume of the 
sample rather than to limit the analysis to the small injected volume.  
2.4.3 Electron microscopy 
The ISEV recommends providing high resolution images of the EVs for a complete 
characterization of the studied preparation. In this project, common electron 
microscopy, scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM) were applied to characterize the EVs. Cryo-TEM was implemented 
by Na’ama Koifman (Technion, Israel).  
In SEM, the image is generated from an intensity map which is gained from the 
detected scattered electron. The focused electron beam scans the surface of the 
sample, scattered electrons are then detected and an image can be composed. For this 
reason, SEM provides information about the sample surface. In TEM the image is 
generated from transmissioned electrons. The resulting image is a two-dimensional 
projection of the sample. Cryogenic EM has a major advantage for the preparation of 
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soft matter samples like EVs: for this method, the sample remains close to its native 
form (Helvig et al., 2015). The sample is fixated by super-cooling. This way, the liquid 
solvent is converted to an amorphous solid state, this is called vitrification. 
Predominantly no ice crystals are formed. Super-cooling must be performed with a 
high cooling rate, which can be realized by the application of liquid ethane. For TEM, 
the sample was dropped onto a carbon grid (Agar Scientific Ltd, UK) membrane, dried 
at RT and then imaged with a TEM (Tecnai G2T20 S-Twin, GEI, Netherlands). For SEM, 
EV suspension was dropped in volumes of 2 µl on a carbon tape. For cryo-TEM 
specimen preparation was performed by Na’ama Koifman with liquid ethane. 
2.4.4 Uptake analysis of EVs by epithelial cells with flow cytometry 
The internalization was determined by flow cytometry of cells that were incubated 
with labeled vesicles. For this experiment, the EVs were labeled with mCling-Atto647 
because of the appropriate excitation and emission spectrum. mCling, abbreviation 
for membrane-binding fluorophore-cysteine-lysine-palmitoyl group, is a membrane 
marker originally designed to track the trafficking of organelles or vesicles. It is made 
up by a membrane-binding fluorophore with a cysteine-lysine-palmitoyl group 
(Revelo and Rizzoli, 2016), in total seven lysines are present. Because of the lipophilic 
chain, mCling easily integrates into membranes and is an easy to handle membrane 
dye. However, removal of excess dye has to be carefully performed because excess 
dye might form micelles or lead to membrane disruption. mCling-Atto647 was 
purchased from Synaptic Systems, in contrary to their protocol it was dissolved in 
DMSO to a concentration of 50 µM. 
Vesicles were diluted to 1010 particles per ml in DMEM without FCS. mCling was 
added 1:50 to a concentration of 1 µM. Excess dye was removed by washing in an 
ultrafiltration (50 K) with 5x of the same volume with DMEM containing 1.5 % BSA.  
BN16 cells were grown in 24-well plates to 80 % confluency in DMEM with high 
glucose concentration and 10 % (v/v) FCS. Cells were washed with PBS and incubated 
for 2 h in DMEM with 1.5 % BSA to prevent unspecific binding on the cells surface. 
Labeled vesicles were added in DMEM with 1.5 % BSA and incubated for the 
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designated time. Duplicates were prepared for each time point. Uptake of vesicles was 
stopped by washing with PBS three times. Cells were trypsinized and trypsin 
removed by centrifugation. Then cells were resuspended in 200 µl PBS with 10 % FCS 
and transferred to flow cytometry tubes. Cells were placed on ice until analysis.  
Flow cytometric analysis was performed with a FACS Canto II. Data was processed 
with the FACSDivaTM Software 6.1.3. Mean fluorescence of all cells was determined 
with the free software Flowing 2.5.1. 
2.5 Animal experiments  
The animals were kept in animal facility of the University Medical Center in Göttingen 
according to the European Convention for the protection of vertebrate animals. All 
experiments were approved by LAVES, the Lower Saxony, Germany, State Office for 
Consumer Protection and Food Safety (file number: 33.9-42502-04-16/2331).  
The animals were fed and given water ad libitum on a daily 12 h light/dark cycle. 
Since it was uncertain whether the smaller, pts-/- animals are able to reach the chow 
in the grid, they were additionally fed mashed food and oats in a petri dish on the 
bottom of the cage beginning the 12th day after birth. 
2.5.1 Ptstm1Thny/ Ptstm1Thny mouse line 
The Ptstm1Thny/ Ptstm1Thny mouse line was kindly provided by Professor Thöny, Zurich, 
Switzerland. Shortly, the mouse phenotype was generated by intragenic deletion of 
parts of the second, the third and fourth exon of the Pts gene. Instead, a cassette 
containing a lacZ and Pgk-neo was inserted (Elzaouk et al., 2004).  
Genotyping was performed with the lyses-kit, NucleoType Mouse PCR. A small piece 
of tale was amputated one day after birth. Tale biopsy was lysed as described in the 
protocol (lysis 2 min at RT, enzyme inactivation for 3 min at 98°C). Then, PCR was 
performed as in the kit recommended for short nucleotide sequences with the 
primers MSY107, MSY08 and PLACZ8.  
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PTPS-activity is undetectable in homozygous mutant mice and these mice die during 
the perinatal period. They can be rescued by feeding tetrahydrobiopterin, but still 
show a very severe phenotype. The mice are treated twice a day and their weight and 
overall performance are recorded. The replacement therapy is made up by biopterin, 
L-dopa, 5-hydroxytryptophan, carbidopa and N-acetyl-L-cysteine according to the 
recipe in table 15 as published by the group of Professor Thöny (Elzaouk et al., 2004). 
Biopterin was administered in tenfold higher amount per BW than for human patients 
lacking PTPS-activity. In our hands, the published treatment with frozen biopterin did 
not work and the protocol was adapted. All compounds except biopterin were 
dissolved and kept in aliquots at -20°C. Biopterin was dissolved freshly a short time 
before gavage to the animal. The pH was adjusted with 1 M NaOH to pH 5-6. Biopterin 
is very unstable at higher pH. Ascorbic acid was not added as described, because of 
the very low pH.  
Table 15: Formula for the replacement therapy of the PTPS-KO mice in accordance to 










2.5.2 Vesicle replacement therapy of FRα-presenting and PTPS-loaded vesicles 
The intranasal replacement therapy was introduced in the third week after birth. 
Every 48 h, the mice were administered intranasally the vesicle-based therapy or 
control treatment. The mice were not anesthetized. They were fixated in upright 
position and the suspension applied alternating to both nostrils in a small volume of 
1 µl per minute. To reduce the stress for the animals and to prevent the suspension to 
be inhaled to the lungs, it is crucial to apply small volumes with time. 1 µl per 1 g BW 
was given up to a maximum of 10 µl. 
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2.5.3 Analysis of the biodistribution by organ screening 
To be able to track the vesicles in vivo, the vesicles were labeled with a near infrared 
fluorescent dye (IRDye800). IRDye800-labeled vesicles were administered 
intranasally to the mice.  
The labelling of IRDye800 based on a NHS ester reacting with all primary aliphatic 
amines in solution was performed as described by the supplier (LI-COR 
Biotechnology GmbH). In short, the vesicles were pelleted and taken up in 50-200 µl 
of PBS in accordance to the pellet size. Protein concentration of the vesicle suspension 
was determined by BCA assay and adjusted to 1 mg/ml. pH value of the solution was 
increased with 0.1 M K2HPO4 (pH 9) in PBS. The solution was placed at room 
temperature. 
The dye with 0.1 mg in one tube was dissolved in 25 µl of ultrapure water. 12.5 µl 
were used to label an aliquot with 500 µg of exosomes in 500 µl. Reaction was 
incubated for 2 h at RT. Unbound dye was removed by dialysis against 5 l PBS at 4°C 
overnight, mildly stirring.  
The quality of labelling was checked by screening of the absorption spectrum of the 
fluorophore. As a control, PBS without any protein or vesicles was labeled in the same 
way and dialyzed. In the dye control almost no absorbance could be detected, for the 
labeled vesicles an absorbance beginning at 650 nm with a maximum at 780-790 nm 
was detected as described by the supplier. 
Healthy mice were anesthetized with medetomidin, midazolam and fentanyl (500 µg, 
5 mg and 50 µg/kg BW, respectively). The BW was determined and the mice were 
anaesthetized by intraperitoneal injection. As soon as the mice were asleep they were 
placed on a heating panel. Eyes were covered with eye salve to protect them from 
dryness. When no hind limb withdrawal reflex could be detected, the vesicle 
suspension was administered with a white tip pipette in a volume of 1 µl in both 
nostrils alternating every minute. 1 µl per 1 g BW was applied up to a maximum of 
10 µl.  
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Then, the mice were antagonized with atipamezol and flumazenil (750 µg/kg BW, 
0.5 mg/kg BW) in 0.9 % NaCl by subcutan administration. Additionally, the mice were 
given 100 µl of 0.9 % NaCl to provide them with liquid. After a defined time frame the 
mice were sacrificed and most organs including the brain screened in the Optix MX2. 
2.5.4 Analysis of the locomotor activity by tracking with an infrared sensor 
The analysis of the locomotor activity of the mice was performed in the fifth week 
after birth. The mice were kept alone in a mouse cage for 24 h once a week. A metal 
mount was installed and a mobile activity monitoring system placed on top. The 
datalogger, MOUSE E MOTION, is able to detect motion with a passive infrared sensor 
in an angle of 41° on the short and 50° on the long side of the cage for a distance of 
5 m. Every second, a motion event can be detected. All motion events are summed up 
for an interval of 4 min. This total number is saved and can be later downloaded in 
context with the light intensity in Lux. Food and water were placed at the bottom of 
the cage to ensure a detection of motion everywhere in the cage. For analysis of the 
results, all data points were summed. This way, all mice were recorded during a night 
and day period.  
2.5.5 Analysis of the strength and motor coordination by Rota rod experiment 
The Rota rod experiment was performed to assess the motor coordination of the 
animals. The experiment was started with 5 rounds per minute (rpm). After 30 s, the 
instrument is set to accelerating mode and the rotating speed increases within 4 min 
in 10 steps to maximum speed. At maximum speed with 40 rpm, the mouse is left for 
one more minute. In this project, the number of rounds was used for analysis. Most 
healthy adult mice are able to maintain running upon the bar during this time frame.  
The pts-/- mice sometimes did not manage to keep up with the rotating speed. Instead 
of falling of the rotating arm, they could cling to it because of their low BW. When this 
happened, and the mouse was not able to return to running on top of the arm after 
three rounds, the experiment was stopped. For evaluation this was taken as a fall off. 






3.1 Purification of extracellular vesicles by chromatographic approaches 
One major milestone of this project was the establishment of a reliable method for the 
purification of extracellular vesicles in a large scale and with a high purity. Most EV-
preparation protocols are based on a separation by size, density or affinity to EV-
enriched proteins. These methods rely on the centrifugation of the particles. Many 
experts are critical about the vesicle integrity and purity after the vesicles have been 
pelleted (Vlassov et al., 2012, Lu et al., 2017). Furthermore, many laboratories might 
not have centrifuges with volumes higher than 50 ml, at least in the 
ultracentrifugation range. For these reasons, this project focused on the 
establishment of an automated, chromatographic purification system.  
One important aspect to consider for the purification of vesicles in chromatographic 
systems is the unusual big particle size. Most chromatography beads, columns and 
resins are not suitable for EVs because of their small pore size. The vesicles are not 
able to penetrate the column material and therefore do not undergo the separation 
but rather pass through in the exclusion volume of the column. In this project, 
custom-made monolithic columns with a pore size of 2 µm were used (BIA 
Seperations d.o.o., Slovenia). 
The samples were prepared in high scale in a production unit as described in chapter 
2.2.1 without addition of FCS to prevent contaminations with external EVs. Before 
application of the sample to the chromatographic ÄKTA-system, they were all 
subjected to a pretreatment, centrifugation for 30 min at 4°C with 4 500 rpm and 
filtration with a 0.4 µm membrane. 
3.1.1 SEC followed by IMAC for purification of his-tagged vesicles 
Another focus of this thesis was laid on the behavior of FRα-presenting vesicles. For 
this purpose, eukaryotic cell lines stably expressing FRα in full length were adapted to 
the conditions in the bioreactor. FRα is attached to the cell membrane by a 




present in exosomes (Admyre et al., 2007, Raj et al., 2012). A signal sequence in the 
C-terminus of the receptor sequence is inducing the binding of the lipid-anchor post-
translationally. For the purification of FRα-positive vesicles, the receptor sequence 
was modified N-terminally with the sequence of a 2his- and 6his-tag. Another cell line 
was established by transfection with empty vector for experiments with native and 
unmodified vesicles as control vesicles. 
A scheme of the purification method for his-tagged vesicles is shown in figure 3.1. It is 
a two-step FPLC method made up by a size exclusion chromatography schematically, 
displayed in A, and an immobilized metal affinity chromatography (IMAC), shown in 
B. After sample pretreatment as described earlier, the sample was applied to the SEC 
with the multimodal material CC700. This material has pores with an activated 
surface for binding of particles smaller than 700 kDa. The large sample volume from 
the bioreactor was applied by a 50 ml sample loop. This way the chromatogram 
resembles a constant elution of the sample rather than showing single peaks. The 
product was collected until UV-absorbance decreased. An exemplary chromatogram 
is displayed in figure 3.1a. 
In the second step, the product of the SEC is directed to the monolithic column 
equipped with iminodiacetic acid (IDA) with immobilized copper. The product of the 
SEC-column is applied with the 50 ml sample loop in several steps and an elution 
protocol with imidazole performed. The chromatographic protocol is described in 
more detail in chapter 2.2.2. Fractions of 2 ml were collected as soon as protein 
elution was detected and peak appeared. An exemplary chromatogram is displayed in 
figure 3.1b.  
3.1.2 IEC for purification of unmodified vesicles 
For the purification of unmodified, native vesicles, a method relying on the surface 
charge of exosomes was developed. Exosomes have areas on the surface that are 
enriched in phosphatidylserine (Heijnen et al., 1999), leading to an anionic surface 
charge. This is why, IEC could be a suitable purification method. Building on the 




equipped with quaternary amines (QA) was applied. These are strong anion exchange 
groups. For this column a protocol with an elution with a strong ionic buffer B was 
performed.  
3.1.3 Improved purification of not modified vesicles by SEC followed by IEC 
For further polishing of the product of IEC, another method with coupling of the SEC 
similar to the protocol for his-tagged vesicles was established and screened for EV-






Figure 3.1: Scheme of two-step FPLC purification of FRα-presenting vesicles.  
A. Samples with his-tagged vesicles are applied to SEC, small contaminating particles are 
retained in the hydrophobic and positively charged pores. The chromatogram resembles a 
flow through rather than a gel filtration as it is expected for this material, Capto Core 700. B. 
Subsequently, the sample is applied to the copper-charged monolithic column. His-tagged 
particles bind to the Cu-atom and are eluted with imidazole. In the chromatogram, the best 




3.1.4 Method optimization of two-step FPLC method with SEC followed by IMAC 
To optimize the described two-step FPLC method based on SEC and IMAC, a 
comparison of different immobilized metals was performed. Therefore, samples of 
2his-, 6his- and untagged vesicles from stably expressing HEK293 cells were 
prepared. Each sample was pretreated as described and run through the SEC-column. 
The IMAC-column was charged with the most common divalent metal cations: cobalt, 
nickel and copper. Copper is supposed to have the highest affinity for formation of 
chelates with polyhistidine-tags but also the lowest specificity. Nickel and cobalt have 
a higher specificity. 
Copper and nickel were purchased as sulfates, cobalt as CoCl2. Charging of the 
monolithic column was performed as described by the supplier. Briefly, the column 
was washed with deionized water, the IDA-ligands cleared with 1 N HCl, washed with 
low ionic charge (0.1 M Phosphate, 1 M NaCl), washed with water and then charged 
with the dissolved metals with a concentration of 30 mM. Each step was performed 
for 20 CV and with a high flow rate of 40 ml/min. 
To investigate the performance of each divalent metal, the column was run with 30 ml 
of each one of the three samples in the following order: not his-, 2his- and 6his-tagged 
supernatant. Between each run, the column was reequilibrated with 5 CV of 500 mM 
imidazole. The chromatograms were analyzed with the software UnicornTM 5.31 and 
areas of the 280 nm absorbance curve of the flow through as well as the peaks were 
integrated. The peak areas were normalized to the initially applied protein amount 
and are displayed in figure 3.2. 
The purpose of application of untagged material to the column was to define the 
background of the column. For every sample, there is unspecific binding of other 
particles because of naturally occurring histidines in the sample. Meeting the 
expectations, the curve of copper showed the biggest peaks, especially in the third 





2His-tagged vesicles always presented higher protein amount in the eluted peaks, 
even though the peak area of the flow through was greater as well. This might indicate 
that the 6his-tagged vesicles remain on the column and are not eluted due to their 
strong binding of the six histidins. The biggest protein outcome could be achieved 
with copper and 2his-tagged vesicles. All following experiments with two-step FPLC 
prepared vesicles were carried out on a Cu2+-charged monolithic column. 
 
Figure 3.2: Comparison of two-step FPLC with different metals in the IMAC column.  
In this experiment, similar amounts of starting material were processed in the two-step FPLC 
method. The amount of protein in the flow through and all peak fractions was determined by 
integration of the area of the 280 nm absorbance curve with the unicorn software. The 
amount was normalized to the starting protein amount. With nickel as a central atom, the FT 
has the highest protein amount, while the peaks have the least. The highest outcome could be 
achieved with Cu2+-ligand with 2his-tagged vesicles. 
All FTs and peaks were analyzed for FRα by Western Blotting. The results were 
complementary to the analysis of the chromatograms. Both, raw sample and eluates 
of the 2his-tagged vesicle samples contained more FRα than the 6his-tagged vesicle 
samples indicating a higher expression level of the former. In addition, the 
6his-tagged vesicles showed almost no FRα in the FT. For this reason, it can be 
assumed that the 6his-tagged vesicles are not completely eluted but partially remain 
on the column. This might result from the higher density of the histidine residues 
present on the surface of the vesicles. 
3.2 Method outcome, purity of the product and reproducibility of the method 
3.2.1 Outcome of the different EV isolation protocols 
There are different methods for the quantification of vesicles and the determination 




amount of protein and particles. In most publications EVs are quantified in protein 
amount (Svensson et al., 2013, Cheng and Schorey, 2016, Nanbo et al., 2013). Since 
EVs only contribute to a small proportion to the total protein amount derived from 
cells and since the amount of particles in fluid samples does not exclusively relate to 
EVs, it is more reasonable to use the terms recovery or output rather than yield. To be 
able to compare methods with each other, the amount of EVs should always be given 
in relation to the starting material rather than indicating a total number. 
First of all, the reproducibility of the method was determined. The CC700 material can 
be used several times for the same kind of sample until a total binding capacity of 
13 mg per ml of packing material is reached. Upon repetitive runs, no loss in product 
amount was observed. The monolithic column charged with Cu2+-ions can be used up 
to three times without being regenerated, but each time a reduction in the protein 
amount of approximately 20 % was observed. All columns can be regenerated and 
recharged several times. 
To determine the EV recovery of the two-step FPLC method made up by SEC 
combined with IMAC, three independent purifications of 2his-tagged vesicles from 
HEK293 cells have been performed. For the purification by IEC, control EVs were 
used. Samples with his-tagged EVs as well as samples with untagged vesicles were 
processed by DC which is the most common method for EV preparation (Théry et al., 
2006). In this project, a protocol with three different centrifugation steps was 
performed. In the first step big particles and debris are removed, in the second 
smaller particles are removed and at last the vesicles are pelleted by 
ultracentrifugation. 
In figure 3.3 the results for the two-step FPLC with the IMAC and the IEC in 
comparison to the most common method by DC are displayed. For the protocol using 
IMAC only samples with 2his-tagged vesicles were used, for the analysis of the 
product outcome of the IEC only untagged vesicles were used. For the results of the 
DC various samples were used tagged and untagged vesicles. All values were 




The protein amount and concentration was determined by BCA-assay. Samples with 
imidazole from the elution buffer were washed in ultrafiltration unit prior 
measurement. Imidazole is absorbing as the bicinchoninic acid-copper complex at 
560 nm and might falsify a BCA-assay. The particle recovery was determined by NTA. 
The CC700 material removes more than half of the contaminating protein amount, 
which is important to remove FRα that might be present in soluble and not vesicle 
bound form. The protein recovery of the DC-protocol is almost four times higher than 
the amount recovered by chromatographic methods. The difference between the 
particle recoveries is smaller, but still the particle recovery of the chromatographic 
purification is smaller. The standard deviation of the particle recovery of the DC is 
higher in comparison to all other preparations.  
Up to now it is not clear to which extent EVs are secreted from cells. This might be 
highly depending on the cell type and the status of the cell. It is not possible to 
estimate whether all EVs are recovered by the described chromatographic or the 
common DC method. In any way, the product of the standard protocol has a higher 
reconstitution of protein and particle amount than the product of the purification by 
chromatography, but shows a stronger variation in the protein and particle recovery, 






Figure 3.3: Particle and protein recoveries of different preparations. 
The protein recovery was determined by BCA-assay and normalized to the amount of the 
starting material. The particle recovery was determined by NTA and processed just as the 
protein amount. The CC700 material is able to remove more than half of the contaminating 
proteins. The IMAC and IEC are able to polish the product further and the protein amount is 
reduced to less than 10 % of the starting material. The product of the DC protocol shows the 
highest recovery of protein amount and particles. However, the purification grade remains 
unclear. 
3.2.2 Purity of the different EV-preparations 
To judge the quality of an EV preparation, different methods for validation of the 
purity are recommended. One of the most common parameters is the ratio of particles 
per protein which is usually given as the ratio of the amount of particles per 1 µg 
protein. It is assumed that EV preparations with less than 1.5 x 109 particles per 1 µg 
protein are not pure, 2 x 109 to 2 x 1010 particles per 1 µg protein are pure and with 
3 x 1010 and more particles per 1 µg protein are considered as very pure (Webber and 
Clayton, 2013). 
The ratio can be easily determined from the particle and protein concentration. For 
the FPLC-methods, the ratios of all steps, from the starting material, the CC700 
product and the IMAC and IEC product were determined. The results are displayed on 
a logarithmic scale in figure 3.4.  
For each sample three or more independent measurements were performed, except 




is noticeable that the purity of the first step, the SEC is low in comparison to the raw 
material. This might be a technical artefact resulting from the detection limit of the 
NTA. The NanoSight is not able to track particles smaller than 10 nm, the CC700 
mainly binds small impurities.  
Even though the difference of the ratio is not significant, the two step affinity 
chromatography has in average the highest amount of particles per 1 µg protein ratio 
and therefore, the highest purity.  
 
Figure 3.4: Purity determined as particle per 1 µg protein ratio. 
For all steps of the two chromatographic methods and for the standard protocol as well as the 
DC, the ratio of particle per 1 µg protein was determined. Protein amount was measured by 
BCA-assay, the particle count was determined with a NTA. For each sample at least three 
independent measurements were performed. Except for the medium, there, only one 
measurement was made. The two-step FPLC method with an IMAC-column has the highest 
ratio indicating the highest grade of purity.  
3.3 Vesicle characterization  
In the next steps, the products of the different EV-preparations were characterized 




exosome enrichment, analysis of single vesicles by electron microscopy, analysis of 
the size distribution by NTA and study of the biological activity. 
3.3.1 Characterization of protein marker 
To facilitate the comparison of different EV purification protocols, supernatant of the 
same cell line was used, i.e. HEK293 stably expressing PTPS-2hisFRα. Aliquots of each 
purification step were retained and the protein concentration determined by BCA-
assay. From each step 1 µg of total protein amount was applied to Western Blotting 
unless otherwise indicated. In the analysis of the IEC column, control cells without the 
stable expression of FRα were used. In addition to the lack of FRα, these cells did not 
contain any TOM20, neither in EV-fractions nor in the raw input material. Therefore, 
the detection of both FRα and TOM20 were omitted. All results are depicted in figure 
3.5.  
GPI-anchored proteins like FRα do not run in sharp bands in the electrophoresis. This 
results from the variable degree of glycosylation of the GPI-anchor (Galian et al., 
2012). The GPI-anchored protein appears with an apparent bigger size in the gel and 
with a smeared band. In these experiments FRα is used as an EV-enriched protein 
together with flotillin and alix which are common exosomal marker (Otto and Nichols, 
2011, Xu et al., 2016).  
For the common protocol by DC, alix is strongly enriched in the EV-pellet, flotillin and 
FRα are not enriched to the same degree. Contaminating proteins like TOM20 from 
the mitochondrial membrane or the stably expressed protein PTPS are reduced. 
When comparing the DC derived vesicles with those derived from the two-step FPLC 
method, the later contained almost no contaminating proteins. In particular, after 
application of the SEC most of extravesicular PTPS is removed. The exosomal markers 
are strongly enriched by the two-step FPLC in 1 µg protein. Peak two, labelled with 
PII, shows the highest amount of the exosomal markers flotillin and FRα.  
The EVs derived from the SEC with IEC purification show a similar enrichment of the 
EV markers when compared to the IMAC methods. The IEC alone shows a smaller 




composition. In peak one (PI) mainly the protein PTPS is eluted. This indicates that 
the SEC purification step is required to remove the bulk amount of contaminating 
proteins and to optimize any further chromatographic purification method. The 
second and third peak of this purification might though contain relatively pure 





Figure 3.5: Exosomal and non-exosomal markers for all FPLC methods in comparison 
with the DC protocol. 
EVs were prepared as described for the specific method. For comparison of DC with the 
chromatographic protocols the same sample from HEK293 cells expressing 2his-tagged FRα 
were used. For the evaluation of the SEC followed by IEC supernatant from HEK293 cells not 
expressing any his-tagged protein was used. For each step and method 1 µg total protein was 
loaded onto a gel, except otherwise indicated. The blots were probed for exosome enriched 
proteins like FRα, flotillin and alix. Additionally, the reduction of intra- and extracellular 




Peak II (PII) of the two-step FPLC combining SEC and IMAC shows the strongest recovery of 
exosome markers while negative markers are reduced. 
Based on the results from the analysis of the EV-enriched and the contaminating 
proteins, the IEC alone shows the worst ratio of the marker proteins. Because of the 
high rate of contaminating proteins the IEC was not further used for EV preparation in 
following experiments. 
The combined procedure of SEC and IMAC shows the best results, since intercellular 
and extracellular contaminations are removed, while EV markers are manifold 
enriched. Even though the DC shows a high ratio of particles per 1 µg protein in 
Western Blot analysis, the high amount of contaminating proteins becomes obvious. 
3.3.2 Size determination of the vesicles  
As suggested from the ISEV, the size distribution was investigated by NTA. Samples of 
each preparation step were collected and adapted to an approximate concentration of 
2 x 108-109 particle/ml. If samples were too concentrated, a dilution in PBS was 
prepared and the measurement repeated. Each sample was analyzed by three 
independent experiments as triplicates for each measurement. 
In general, the mean size of the prepared EVs is similar when comparing the 
mentioned purification methods. The raw material and the product of the SEC show a 
higher degree of variability than the final products. By application of the CC700 
purification step, most proteins and most small particles are removed and the mean 
size increases when compared with the raw material. Peak three (PIII) from the 
purification with SEC and IEC was recognized as the main EV-containing fraction by 
Western Blot analysis. The size of the particles eluted from the IEC-column is on 
average smaller than the size obtained by IMAC. These results are shown in figure 3.6. 
The size of the particles obtained from the SEC followed by IMAC was increasing, peak 
I to III. According to Western Blot analysis peak fractions with the highest amount of 
exosomes is PII. The particles in this fraction are close to the maximum size of 




mean and median size. The difference of the mean and median size of the DC 
preparation is significant in contrary to all other aliquots. This indicates a 
considerable population of small particles in this sample. 
 
Figure 3.6: Average and median size of each purification step determined by NTA. 
The control EVs were prepared by SEC followed by IEC. Vesicles presenting 2his-tagged FRα 
were purified by the described two-step FPLC method. The exosome preparation obtained 
from DC, labeled as P100, show the highest difference between the mean and the median size. 
This indicates that particles obtained by DC are highly variable in size and particularly 
contain higher proportions of particles smaller than the mean size. The products PI-PII from 
two-step FPLC protocols are more homogenous, especially in PII of SEC and IMAC. The 
particles obtained by SEC are more heterogeneous and show a large variation in size. 
3.3.3 Characterization of single vesicles 
To characterize single vesicles, obtained by the different protocols, samples were 
prepared as described above. FRα-presenting vesicles were gained from supernatant 
of HEK293 cells stably expressing 2hisFRα. All electron microscopic images were 
made at the Technion in Haifa, Israel with the kind help of Professor Sosnik’s group.  
For SEM, the EVs were dropped onto carbon-tape, dried and covered with Au/Pd-
coating. The vesicle preparations show a cup-shaped morphology that is 
characteristic of exosomes (figure 3.7a and b). The collapsed impression is a technical 
artefact resulting from drying of the sample. Larger vesicles were sucked by the 
vacuum and lead to the black holes visible in figure 3.7a and b. The vesicle 
preparation appeared uniform and there were almost no contaminations of debris 




By transmission electron microscopy a higher resolution can be achieved but the 
sample is degraded very fast. In figure 3.7c many vesicle parts are visible which 
degraded while taking the image. Dark spots in TEM may relate to lipoproteins as 
seen on the left side of figure 3.7c. It was even possible to capture the double 
membrane of an exosome as nicely depicted in figure 3.7d.  
 
Figure 3.7: Electron microscopic examination of vesicles purified by SEC and IMAC. 
Samples were prepared by two-step FPLC-method as described. FRα-presenting exosomes 
from HEK293 cells in A and B imaged by scanning electron microscopy. The vesicles are of 
exosome-like size <200 nm and cup shaped. As shown in C and D, a homogenous size 




For native EV isolated by SEC combined with IEC, it was not possible to take images of 
single vesicles in TEM or SEM. After analysis in cryo-TEM by Na’ama Koifman, who is 
specialized on the imaging of EVs, it became clear that many lipoprotein particles 
were present in these preparations, as indicated in figure 3.8a by white arrow heads. 
In contrast to EVs lipoprotein particles are not enclosed by a double membrane and 
show a more homogenous structure than vesicles as nicely demonstrated in figure 
3.8c. For cryo-TEM, the sample does not need to be dehydrated. This is the major 
advantage in comparison to other EM imaging techniques. This way a more native 
form for image taking is preserved. In this case, the analysis of cryo-TEM images 
revealed the presence of some multilamellar vesicles as visible in figure 3.8b.  
 
Figure 3.8: Cryo-TEM of native EVs purified by SEC coupled with IEC.  
The sample was purified as earlier described by SEC and IEC of HEK293 cells. The specimen 
preparation for the cryo-TEM images were made by Na’ama Koifman. The images revealed a 
high amount of lipoproteins as indicated in A by the arrows. There are exosome-like vesicles 
with a double membrane and a heterogeneous interior as seen in C. Multilamellar EVs can 
occur, shown in B.  
3.3.4 Density of the different EV-preparations in comparison 
Additionally to the characterization requested by ISEV, the density of the different EV 
preparations was determined. Since the established method is based on purification 
by size and affinity, the density is a parameter that can give further information about 
the isolated particles. Both, samples from the two-step FPLC and the DC method were 




up with decreasing concentration. The sample was added in 0.25 mM sucrose in the 
same volume. Samples were taken from HEK293 stably expressing PTPS-2hisFRα. In 
two independent experiments, a sample was purified with the two-step FPLC method 
and in parallel by DC. From each layer the same volume of sample was subjected to 
Western Blotting and analyzed for the presence of flotillin and FRα. One exemplary 
blot is shown in figure 3.9. For evaluation, the images were analyzed with image J. All 
pixels of one sucrose gradient were summed up to 100 % and each band was 
normalized to the total pixel amount. These results are summarized in bar diagram 
above the associated Western Blot image in figure 3.9. 
The particles purified by two-step FPLC reached their equilibrium density at 
1.16 - 1.19 g/cm3. Though, the isolated vesicles were slightly bigger in size, the 
density corresponds to exosomes perfectly well. The increased size might results 
from the fact that the cell lines overexpress FRα. and PTPS. In fact, the control cells 
without overexpression show normal sized EVs.  
For the EVs derived from the DC, two distinct populations could be distinguished. The 
density of one of them is similar to the density of exosome-like EVs obtained from the 
two-step FPLC product at 1 - 1.19 g/cm3 whereas the second one with a higher 





Figure 3.9: Density determination of EVs prepared by DC and in two-step FPLC 
determined by centrifugation on a sucrose gradient.  
EVs were prepared by two-step FPLC and DC, followed by a separation by centrifugation in a 
sucrose gradient for 16 h with 100.000 x g. Data was taken from two independent 
experiments. The EVs resulting from purification by the established two-step FPLC method 




3.3.5 Verification of FRα on the surface of the isolated vesicles 
To verify the amount of FRα-presenting vesicles in the final FPLC product with the 
help of NTA, an indirect labeling similar to a labeling protocol for flow cytometric 
analysis was performed. Therefore, the raw material, the product of the SEC-column 
and the second peak fractions of the elution from the IMAC column were diluted to an 
appropriate concentration, labelling with a primary antibody against FRα, MOV18 
added, washed and labeled with a secondary, fluorescence-conjugated antibody. The 
sample was gained from supernatant of HEK293 cells stably expressing 2hisFRα. 
In figure 3.10 the results of this experiment are depicted. Three curves of the size 
distribution corresponding to three independent experiments are exemplary depicted 
as solid, dashed and dotted lines. The size distribution of the fluorescent particles is 
displayed in blue color, the black lines resemble recordings of all particles. In 
comparison to the laboriously purified SEC- and final FPLC-product, the raw material 
contains a high amount of labeled particles. This might result from a high number of 
soluble FRα in the beginning, which is then removed by SEC.  
The FPLC-derived EVs are almost exclusively FRα-positive as demonstrated by the 
bars in the graph on the right side. However, there is still a considerable amount of 
particles in this sample that are not fluorescent and therefore not FRα-positive. Most 
contaminations are of small size and were not detected in the other sample 
preparations. However, these particles are too small to be regarded as EVs. They are 
smaller than 30 nm.   
In conclusion, the analysis of FRα-positive particles during every purification step 





Figure 3.10: Analysis of fluorescent particles by indirect antibody labeling in NTA. 
Each preparation step was labeled with anti-FRα-antibody from mouse, MOV18, washed and 
then labeled with a secondary antibody conjugated with anti-mouse IgG Alexa Fluor532. The 
samples were not further processed but analyzed by NTA for all (black) and fluorescent 
particles (blue). In the left column the size distribution of one analysis from three 
independent experiments is depicted as solid, dashed or dotted line. The right column 
displays the average amount of all (black bar) and of the fluorescent particles (blue bar). The 




3.3.6 Analysis of biological performance by EV uptake  
It is difficult to prove the biological activity and integrity of EVs. The uptake of cells 
demonstrated by microscopy and by flow cytometric analysis are used in other 
scientific groups (Balaj et al., 2015, Escrevente et al., 2011). In this project, a flow 
cytometric analysis of the up taking cells was performed. Therefore, the vesicles are 
labeled and added to the cells which are then screened for the fluorescent signal. In 
this case, the dye mCling was applied. mCling was originally designed for the 
visualization of synaptic vesicles (Revelo et al., 2014). The dye is made up by a poly-L-
lysine tale bound to a fluorescent molecule, in our case ATTO647. Poly-L-lysine is a 
lipophilic tale that easily integrates in membranes.  
Vesicle labelling was performed with concentrated vesicle suspensions for a short 
time of a few minutes. Unbound mCling was removed by ultrafiltration with 
Hydrosart. Due to the hydrophobic tale, mCling will tend to form micelles which might 
behave like vesicles and might not be removable by ultrafiltration units. For this 
reason, a control with just dye, which was also washed, was included. It is referred to 
as mCling and depicted as green-dot in figure 3.11.  
In parallel, vesicles without FRα were purified by DC and labeled in the same manner. 
For the experiment shown the particles in the final product were counted with NTA 
and added in the same number as described in section 2.4.4.  
BN16 cell line was chosen for this experiment. This is a cell line of epithelial cells, that 
are able to polarize just as choroid plexus cells, where the FRα is taken up. The cells 
were grown to 60 % confluency and labeled vesicles added for different periods of 
time from 5 min to 16 h. 10 000 cells were counted by flow cytometry and the mean 
fluorescence of all cells taken for analysis. The FRα-positive vesicles are taken up 
faster and lead to a higher mean fluorescence of the cells. The experiment was 
repeated with the same conditions, except the vesicles were not counted by NTA but 
quantified according to their protein amount. The result was similar; the uptake of 




After 8 h, a saturation of the uptake is reached. The fluorescence even decreases after 
16 h. This will be presumable a technical artefact resulting from the procession of the 
vesicles and with them the fluorophore leading to a reduction of the average 
fluorescence. Another explanation might be that some vesicles are secreted and 
therefore, the overall fluorescence reduces.  
 
Figure 3.11: Quantification of EV uptake of BN16 cells quantified by flow cytometry. 
BN16 cells were grown to 60 % confluency in a 24-well plate. FRα-presenting and control EVs 
were labeled with mCling-ATTO647, washed in a Hydrosart ultrafiltration device and added 
to each well. A dye control consisting of dye without vesicles was subjected to the same 
protocol and added. Cells were harvested with trypsin and uptake was quantified by analysis 
of mean fluorescence by flow cytometry. FRα-presenting vesicles are taken up faster than 
control vesicles.  
3.4 Cargo loading 
There are many ways to introduce drugs into extracellular vesicles. In case of small 
molecules it might be sufficient to initiate the formation of pores into the double 
membrane and enable the drug to flow in the vesicles along a concentration gradient. 
However, it is not possible to target high amounts of the cargo into the vesicles since 
the vesicles volume is rather small in relation to the total volume. For example, 




concentration of 1012 particles per ml. Presumed these EVs have a theoretical 
diameter of 100 nm, they would have a theoretical total volume of 0.52*10-3 ml or 
0.052 %. Since, it is not possible to increase the targeting of molecules into vesicles 
without any molecules that promote an active transport, the concentration of the drug 
corresponds inside and outside the EVs with each other; therefore, the total amount 
of the drug that is encapsulated into the EVs only equals 0.052 % of the total amount 
of the drug that was added to the total volume of EV solution. 
3.4.1 Loading experiments with the TPPI assay 
To be able to detect very low amount of loaded protein to EVs, a very sensitive assay 
needed to be found for the extracellular loading experiments. In this project the 
enzyme TPPI was chosen, since there is such assay established in our laboratory for 
dried blood spots (Lukacs et al., 2003). This assay allows the detection of the 
proteinase in the low nanomolar range. The activity can be measured after one hour 
of reaction by cleavage of the substrate Ala-Ala-Phe-7-amido-4-methylcoumarin. 
Fluorescence emission is measured at 460 nm after excitation at 355 nm. With the 
help of a calibration curve of 4-methylcoumarin, the amount of cleaved substrate and 
the concentration of TPPI can be determined. Other proteases are inhibited by 
pepstatin A and E64. 
EVs were harvested from supernatant of cells stably expressing FRα and TPPI. This 
way, EVs contained a small amount of TPPI and had a basal TPPI activity. The basal 
activity of EVs in approximate concentration of 1012 particles per ml was below 
50 nmol/h/ml TPPI activity. TPPI was added to the loading experiments in 
concentration of 0.052 % to 1.2 mg/ml and protease activities higher 
18 500 nmol/h/ml. This would result in at least 74 nmol/h/ml, if 0.052 % would be 
recovered. The basal activity of these EVs is used as 100 % for the visualization in 
figure 3.12. 
TPPI is a lysosomal protease, that is expressed as a preprotein and subsequently, is 
proteolytically activated by cleavage in the lysosome (Guhaniyogi et al., 2009). The 




investigate the loading of the different isoforms of TPPI, the experiment was 
performed at different pH values starting at physiological pH of 7.4 and at lower pH 
values.  
Additionally, saponin and chlorpromazine were used to introduce pores into the 
vesicles. Chlorpromazine embeds in the inner membrane leaflet of cell membranes 
and therefore leads to a deformation of the cell morphology from discocytes to 
stomatocytes (Favretto et al., 2013). Since, this process is reversible just as the 
incorporation of saponin, these reagents are suitable for the loading of clinical grade 
vehicles. Saponin was used at 0.2 mg/ml and chlorpromazine at 200 and 100 µM.  
Another described method is the loading by hypotonic dialysis. For this purpose, the 
EVs are incubated in hypotonic solution to induce a swelling and dissociation of the 
membrane, in this case in diluted PBS (70 % PBS). TPPI was added at 1.2 mg/ml for 
1 h at 4°C stirring in a dialysis tube. Subsequently, the vesicles were introduced to 
hypertonic solution, twofold concentrated PBS (200 % PBS). Then, the vesicles were 
washed with a commercial SEC-column, qEV. In these experiments, the amount of 
TPPI-activity in the recovered vesicles was even reduced in comparison to the control 
EVs.  
Electroporation is a common method for the transfection of cells. Cell membrane can 
be porated by application of an electric field with usually thousands of volts (Liang et 
al., 2015, Chang et al., 2016, Ghanta et al., 2018). For exosomes, electrical fields with 
lower voltage have been described (Alvarez-Erviti et al., 2011). This experiment was 
performed with 400 and 750 V in a Gene Pulser Xcell in a 4 mm cuvette. To allow the 
membrane to close the pores the vesicles were recovered for 30 min at 37°C. After 
loading, the vesicles were regained by purification with a qEV column to remove 
excessive TPPI. In my hands, the electroporation of EVs was not successful and it was 
not possible to retrieve any TPPI in the vesicles. The amount of TPPI in the regained 
fractions from the qEV column did not show any in- or decrease as depicted in figure 






Figure 3.12: Extracellular loading of TPPI into EVs. 
EVs were treated with different reagents, hypotonic dialysis an electroporation to introduce 
pores to the membrane and allow the entrance of TPPI. In summary, the artificial loading 
procedures had no effect or even led to a reduction of the existing basal TPPI-amount. 
In literature, there is one new approach described for the engineering of exosomes by 
means of fusion with liposomes (Sato et al., 2016). The liposomes are specifically 
designed with the desired surface molecules or lipid composition and then are fused 
to exosomes by a freeze-thaw method to overcome the hydrophobic properties of the 
lipid layers (Sato et al., 2016). With the kind help of Jan Wehland from Professor 
Diederichsen’s group, a similar strategy was approached in this project. Liposomes 
with TPPI were prepared by extrusion with a small diameter of 100 nm. These TPPI-
carrying vesicles were added to exosomes. The attempt was to simply open the 
vesicles by extrusion and fuse with the fusogenic and small liposomes. The product 
was purified with a qEV column. The data is not shown, but in the end, only a 
reduction of the basal TPPI concentration could be observed. 
As a result of the experiences with the exogenous loading, no further exogenous 
loading experiments of vesicles with proteins were performed. Further, the amount of 
TPPI contained in EVs required to treat TPPI deficient mice efficiently was assessed. It 
was calculated that at least 10 µg of TPPI in a maximum volume of 10 µl would be 
necessary to substantially provide TPPI to a mouse’s brain. Since, the estimated 
amount of TPPI to be encapsulated by exosomes was below 0.1 µg per injection 




3.4.2 Endogenous loading of PTPS 
Since EV-associated TPPI activity was generally higher by endogenous loading of the 
cell, further experiments were performed to enhance endogenous drug loading. PTPS 
is located in the cytosol and might be therefore preferentially be packed into 
exosomes since these intraluminal vesicles are formed within MVB by invagination of 
the cytosolic matrix. These vesicles carrying PTPS are then excreted as exosomes.  
PTPS catalyzes the formation of 6-pyrovyol tetrahydropterin from 
7,8-dihydroneopterin triphosphate. There is an activity assay that is very sensitive to 
oxidation and the substrate 7,8-dihydroneopterin cannot be stored but is prepared in 
situ. The quantification of the PTPS loading was performed by Western Blotting and is 
summarized in figure 3.13. Since Western Blot analysis is a semi quantitative method, 
the samples were additionally sent to Professor Thöny’s group where Tanja Scherer 
kindly performed a PTPS activity assay. The samples were prepared in Göttingen. 
Before shipping, the vesicles were ultracentrifuged to pellets and then sent on dry ice 
to Zurich.  
It was published that some toxins are able to intervene in the endosomal pathway and 
are packed into vesicles in the MVB. They are then released in exosomes and 
overcome not only the lysosomal degradation but are also bypassed to other cells 
(Zhang et al., 2009). This phenomenon was described for K562 cells. For this reason, 
additionally to the HEK293 cells in this experiment K562 cells stably expressing 
PTPS-2hisFRα were grown and adapted to the MINIPERM® bioreactor. Supernatant 
was collected and 2his-tagged FRα-positive vesicles purified as previously described 
by SEC followed by IMAC. From each purification step and similarly as for the 
purification from HEK293 cells 1 µg was applied to analyze by Western Blotting.  
For comparison, the samples were also analyzed for FRα as depicted in figure 3.13. 
For FRα, the enrichment per 1 µg total protein is nicely visible in PI and PII for both 
cell lines. The concentration of FRα is very high, while the endogenous PTPS remains 
undetectable. In case of PTPS, it is the other way around; the amount per 1 µg protein 




to the EVs in the cell line K562 but in relation to the amount of pixel present in the 
first line, in the raw material of the cell line per 1 µg protein, the protein is only 
slightly higher recovered in EVs than in HEK293 as visualized in a bar diagram in 
figure 3.13b. The choice of K562 as cell line for targeting of the overexpressed protein 
had no significant effect. 
Targeting of the protein PTPS to the vesicles was also performed by introduction of a 
membrane tag. In this project a short sequence of GAP43 was used. The short 
sequence encodes a palmitoylation sequence of growth-associated protein from the 
nervous tissue. Vesicles from cells that were engineered to express PTPS with the 
small tag, GAP43-PTPS, show an enrichment rather than a reduction in the vesicle 
preparation. The enrichment in the EV fractionis threefold higher than without 
tagging. A significant proportion of GAP43-PTPS was purified from the supernatant of 





Figure 3.13: Endogenous loading of a drug protein to EVs quantified by Western Blot 
analysis. 
His-tagged vesicles were isolated from supernatant of stably PTPS expressing cell lines, 
HEK293 and K562, in comparison with a GAP43-tagged version of PTPS analyzed by Western 
Blotting. The highest amounts of PTPS were found in EVs for the GAP43-tagged protein. PTPS 
is enriched in PI and PII just as FRα. For HEK293 and K562, only traces of the originally 
present PTPS are recovered in EVs. 
These results were underlined by the PTPS activity assay. It was determined that 
K562 cells expressing PTPS showed 63.43 µU PTPS-activity per mg protein while 
HEK293 had a slightly reduced amount in their EV fraction with 54.25 µU per mg 
protein. The GAP43-tagged version PTPS showed a stronger targeting to EVs with 
132.57 µU per mg.  
3.5 Analysis of biodistribution of the vesicles after intranasal application  
To investigate the faith of intranasally administered EVs, the EVs were labeled with 
near infrared fluorescent dye. For this purpose, the vesicles needed to be pelleted by 




EVs were gained from supernatant of HEK293 cells stably expressing FRα. For 
comparison of the distribution, FRα-negative, native vesicles were recovered by DC 
from HEK293 transfected with empty vector. 
The mice were narcotized and placed onto a warming plate. The vesicles were applied 
in small steps of 1 µl per min in each nostril alternating up to a total volume of 10 µl. 
Then, the mice were awaken, sacrificed and the organs screened for fluorescent signal 
of the vesicles imaging in an Optix 2. 
Background fluorescence of the organ was measured and subtracted. Overall, the 
fluorescence signal of the intranasally applied vesicles in the organs was very low. For 
both, the FRα-positive and -negative vesicles, there was some signal in the brain but 





Figure 3.14: Biodistribution of FRα-presenting and control EVs. 
FRα-presenting and control EVs were labeled with IRDye800 and administered intranasally 
to healthy mice. Treatment was performed under anesthesia and the mice were awakened 
after treatment. After the defined time periods the mice were sacrificed and their organs were 
screened for fluorescence. A. Comparison of the brains of the treated mice, the dye-control 
and an untreated mouse. Overall, the signal was very low. B. Three mice were treated with 
10 µl of 1 mg/ml concentrated and labeled EVs. There is no significant difference in the 
uptake by the brain of control EVs and FRα-positive vesicles. C. The dye alone reoccurs after 6 
and 12 h in liver, kidney and the brain. The EVs behave like liposomes and can be detected 
after 24 h in the liver. 
The dye had a maximum signal in the organs after 6 to 12 h. In contrast to the EVs that 
behaved differently. Especially in the liver, the amount of fluorescence was increasing 
after 24 h. This is an observation from the liposomes field; the vesicles are circulating 
in the system and then accumulate in the liver, at least for i.v. application (van der 




3.6 Investigation of the drug vehicle capacity of the FRα-presenting EVs 
equipped with therapeutic cargo 
For the investigation of the exosomes as drug delivery vehicles in vivo, the mouse 
model of a biopterin disorder was chosen. Since the enzyme TPPI could only be 
loaded in very low amounts, the mouse model of CLN2 was excluded.  
The knockout mice (KO) were generated by mating of heterozygous mice of the pts-/- 
mouse line. All born pups were initially treated by the substitution therapy until a 
genotyping was performed with tale biopsies. Then, only KO and control mice were 
treated. KOs treated as published by Elzaouk et al. showed the described growth 
abnormalities, were less active and had difficulties in swallowing (Elzaouk et al., 
2003). In average, a BW of 8.0 ± 0.3 g was reached calculated as the mean of four KO 
animals. Wildtype or heterozygous knockout mice reached an average weight of 
17.7 ± 0.3 g at this age of 31 days.  
The first treatment approach of the KO mice was performed by oral gavage. There is 
evidence of exosome uptake upon oral administration (Munagala et al., 2016). Two 
mice were treated with exosomes administered orally in parallel to the oral 
substitution treatment published by Elzaouk et al. that is necessary to rescue the mice 
(Elzaouk et al., 2003). The general health of these two mice rather deteriorated 
throughout the treatment. They did not show any improvement in the growth rate. 
Both mice developed more symptoms like apathy and a strongly bend posture which 
is an indicator of pain. After approximately 25 days, they had to be sacrificed. 
Behavioral experiments could not be performed. The growth curve of these mice are 
depicted in figure 3.15a. In parallel, two wildtype mice were treated in the same 
manner with exosomes. One of these two showed a stronger growth than normal mice 
and died unexpectedly after 22 days. The growth curve of the two orally treated mice 
is displayed in figure 3.15c in blue. These results might indicate that FRα-presenting 
vesicles are not taken up in the intestine but for therapeutical purpose need to be 




Before performing experiments with PTPS loaded vesicles, a control with direct 
application of the purified and vesicle-free enzyme PTPS was done. For this purpose, 
PTPS was purified by a his-tag using a commercially available IMAC-column. The 
protein was rebuffered in PBS and the concentration adjusted to the concentration 
achieved by exosomes being targeted EVs by GAP43-tag. The activity of the 
recombinantly produced PTPS was verified by an activity assay in fibroblasts that was 
performed by our cooperation partners in Zurich (Thönys group).  
The mice were treated intranasally every 48 h with 1µl of enzyme suspension per 1 g 
BW up to 10 µl. The animals accepted the slow application into the nose. The mice 
never showed any shortness of breath. The aim of the very slow application was, 
apart from stress reduction, to achieve a slow uptake of the vesicle suspension 
through the nasal mucosa. Otherwise the suspension could be inhaled and get to the 
lung.  
These two KO mice treated with vesicle-free PTPS survived 27 days before they had 
to be sacrificed because of a reduction of the health. They did not show any significant 
increase in their growth in comparison to the KO animals treated without any PTPS. 
The vesicle-free enzyme seems not to be able to pass through the nasal mucosa and to 
reach the central nervous system. These mice had to be sacrificed before they were 
able to reach 28 days and first behavioral experiments could be performed. The 
growth curve of these mice in visualized in figure 3.15b as blue curves.  
Approximately after 3 weeks mice are fully weaned by the mother mouse and all mice, 
KO and WT, showed growth retardation for a few days. In this time frame the KO mice 
were struggling even more. The orally treated KO mice and the PTPS control mice 





Figure 3.15: Growth behavior of KO and control mice treated with exosome and the 
control treatment. 
PTPS KO, WT and heterozygous KO mice were treated with the respective therapy and their 
weight determined. When not differently indicated one exemplary mouse is depicted. For 
groups in which 3 or more mice were treated an average with the standard deviation is 
depicted. In A and B treated (blue and grey) and untreated (black) KO mice are depicted. In A 
two animals were given exosomes orally. These mice had rather a worse health condition 
than the control KO mice and had to be sacrificed. In B the mice were treated intranasally. 
Two mice were given PTPS, one died and one had to be sacrificed. The group of exosome-
treated mice survived and even showed a significant higher weight curve. In C and D healthy 
mice were treated by corresponding settings. The growth behavior of the healthy mice was 
mostly unaffected by the treatment. 
The oral application of exosomes did not show any improvement in the growth 
behavior and health condition of the KO mice. Other modes of application 
intraventricular injection or intranasal administration are targeting the vesicles to the 
CSF. For the intraventricular injection, a cannula is implanted through the cranial 
bone directly connecting to the ventricles. To ensure a stable fixation of this cannula, a 
mouse must be at least 3 weeks old and weigh more than 10 g to have a bone 
structure that is stable enough. For this reason, the intranasal administration route 
was the only one applicable for the PTPS KO mice. The established GAP43-PTPS 
enriched EVs were used. KO and WT mice were treated by daily substitution therapy 




concentration of 0.1 mg/ml. The weight of the mice was monitored daily and the 
results are summarized in figure 3.15b as grey curve. 
From the very beginning the exosomes treated mice showed a better overall 
performance compared with the not EV-treated KO mice. During the first days, it was 
even not possible to distinguish the afflicted animals from their healthy littermates. 
This improvement of the overall performance reflects in the BW of the animals. The 
treated KO mice showed a slightly stronger increased growth rate than not EV-treated 
KOs. From the 27th to the 30th day after birth, the weight of the EV-treated mice is 
significantly higher than of the untreated. These mice were even able to gain weight 
after the critical time of the third week. It seemed like they would continue growing 
and almost complete recovery was achieved by the EV delivered PTPS. But, after 
approximately 4 weeks, the mice began to show more symptoms and the growth rate 
decreased. Up to the end of eighth weeks the animals were able to maintain their 
weight and presented a higher overall performance.  
The WT mice treated intranasally with exosomes did not show any adverse effects. 
They presented a slightly lower average BW than the untreated WT mice. One 
heterozygous mouse treated with exosomes had a strongly reduced growth rate; it 
remained very small, almost as small as the KOs and did not become heavier than 12 g 
at the end of the experiment. This might explain the large standard deviation of the 
curve, depicted in figure 3.15d in grey. 
The intranasal administration seemed to be accepted well by the animals. They did 
not show any infection or adverse effects of the nasal mucosa.  
3.6.1 Analysis of the overall performance of the EV-treated KO mice 
In addition to the BW, more parameters were acquired on the health of the treated 
animals. For this purpose, two behavioral tests were performed. The first assay was 
the determination of the performance by tracking their locomotor activity in their 
home cage for 24 h once a week. This observatory test seemed very promising 
because already by eye examination for short time a difference between the activity of 




Rota rod test. In this test, the mice are placed on a rotating bar and the speed of 
rotation is increased. Most healthy mice are able to stay on the bar. The KO animals 
often were not able to keep up the speed. In contrary to the healthy mice, they were 
able to clench to the bar and rotate with it. 
The results of the behavioral tests are depicted in figure 3.16. In A, the results of the 
activity assay for the healthy and the affected mice are summarized. The difference 
between WT and KO animals is significant, but no effect of the exosome treatment can 
be detected. In contrary to the observation of the examiner, these mice were not more 
active and did not move more than the normally treated KOs. The EV-treated WT mice 
showed a decreased activity but the difference is not significant.  
A significant difference was obtained in the Rota rod experiment in the performance 
when EV-treated and the not EV-treated KO mice were compared. In this experiment, 
the EV-treated KOs performed equally well with the healthy mice and could run on 
the bar until the end of the experiment. For the healthy animals, no difference, except 
in the 6th week after birth was detectable. In this case, the EV-treated mice showed a 
better performance and all mice were able to stay on the bar until the end of the 






Figure 3.16: Performance of the WT and the KO mice in the behavioral tests. 
KO and healthy mice treated with PTPS-carrying exosomes and the untreated control mice 
were screened for their performance by A detection of their locomotor activity in the cage 
and B their performance in the Rota rod experiment. For the healthy mice in both 
experiments almost no difference for the treated and untreated mice could be measured. The 






This present study investigates the question whether extracellular vesicles can be 
utilized as drug delivery vehicles. Further, our investigations address the following 
aspects of biopharmaceuticals: purification from biological source, cargo loading, in 
vitro and in vivo performance and finally the therapeutic capacity of the designed 
formulation. 
4.1 Successful isolation of EVs in a high quality by chromatographic approach 
The research field around EVs is quite young one and many fundamental questions 
are still not clarified. There are no clear definitions of the different types of EVs, 
neither the size or density nor exclusive protein markers could be identified yet. The 
situation is even more complicated by the fact that many purification and analysis 
methods result in an alteration of the vesicles, e.g. from shear forces and aggregate 
formation. Facing these challenges and uncertainties, everybody performing research 
on EVs needs to work very cautiously and to take into account all available tools to 
put the puzzle together.  
The gold standard protocol for EV preparation, for microvesicles and exosomes is the 
DC (Momen-Heravi et al., 2013). The other commonly used and regarded as the 
superior method is the density gradient (Lobb et al., 2015). According to the literature 
and claimed by a company, the product ExoQuickTM, a new purification kit based on 
the precipitation of the vesicles by PEG, promises an easy and quick purification in 
one step (Antes et al., 2015). Even though a high purity in combination with a high 
yield is described, a major drawback is the polymer PEG which is difficult to remove 
from the vesicles (Li et al., 2017). The advantage of methods based on centrifugation 
is the availability in most laboratories. However, vesicles undergo shear forces and all 
these protocols are limited to sample volumes complying with the centrifugation 
flasks. 
Another size-based approach is the SEC. There are commercially available columns 




undergo great mechanical stress and remain in their physiological form. On the other 
hand, the maximum volume of these products is 10 ml. In this project, a 
chromatographic method with a SEC coupled to an affinity chromatography was 
established. This protocol unifies many benefits: high volumes of sample can be 
processed, the mechanical stress is limited and the system can be reused several 
times. The method has drawbacks, e.g. not every lab has a suitable chromatographic 
system, the protocol establishment is very time consuming and only large amounts of 
sample can be processed. The recovery of protein and particle amount is for all 
methods very low. The two-step FPLC method for his-tagged vesicles recovers only 
1.5 ±1 % of the originally applied protein amount. The DC protocol in contrary 
maintains 5.0 ± 2 % of the original protein mass. Many methods are in criticism for 
their low yield. But, up to now, there is little data on the amount of exosomes being 
secreted by cells. For this reason, the yield of an isolation method can hardly be 
judged at the current state of knowledge. A high recovery of protein amount can also 
be an indicator for protein contaminations. 
Even though the newly established method results in lower particle and protein 
recovery, the purity associated for this method is higher. The purity of the product 
was calculated by the ratio of particles per 1 µg protein. The ratio of the two-step 
FPLC method is superior in comparison to the standard protocol using DC.  
In this project the IEC did not work well for extracellular vesicles. When only IEC was 
applied many intercellular contaminations remained in the preparation as visible in 
the Western Blot analysis in figure 3.5. In general, it is not advisable to rely on one 
isolation technique for EV preparation. The protocol coupling SEC and IEC showed a 
relatively high purity in the particle-per-protein ratio, but in the EM analysis revealed 
that this preparations contained a high amount of contaminations by lipoproteins. 
The IEC protocol is based on the surface charge of the vesicles. though, it is not shown 
for all exosomes to have an increased amount of PS and a negative surface charge, 
since this is also an “eat-me” signal that would lead to a clearance in the system 
(Skotland et al., 2017). These results from this project indicate a more complex 




The results of the IEC purification demonstrate once more the necessity of a complete 
characterization of an EV preparation. The particles of the preparation had the right 
size and reasonable ratios in particle per protein analysis. Only the EM was able to 
reveal the high proportion of contaminating lipoproteins. 
Apart from the enrichment of exosomal markers and the reduction of contaminating 
proteins, the size and density of the vesicles recovered by SEC followed by IMAC 
correspond to exosomal features. They have a mean size of 177.7±28 nm. These 
samples contain a high amount of alix which represents a specific marker from the 
exosomal pathway and in addition, these fractions also contain flotillin2 as seen in 
figure 3.5 which is present in other EVs as well.  
Analyzing the size and density of the different preparations, the product of the two-
step FPLC method is more homogenous than the product of the DC protocol. At this 
point it needs to be considered that the raw sample used in this project is not a native 
sample, but supernatant from transfected cells. This overexpression most likely 
affects the vesicle populations in the sample. In the analysis of the density it stands to 
reason that the population recovered by DC is different than the one gained by two-
step FPLC. 
In general, the question whether these designed vesicles are exosomes will be 
discussed in the following lines. The EM-images show EV-like vesicles. The proteins 
found in the preparations are EV-enriched proteins (alix, FRα) and contaminating 
proteins are reduced (TOM20). Flotillin2 can also be a marker for microvesicles 
(Simpson et al., 2008). Despite these numerous proves for the EV-like features of the 
preparation, it is possible that this vesicle population is mixed. However, almost all of 
these particles are FRα-presenting as could be proven by fluorescent particle analysis. 
Nevertheless, a purification of microvesicles secreted from the plasma cell membrane 
with his-tagged FRα cannot be excluded. These vesicles would not be discriminated in 




4.2 Loading of therapeutic proteins to vesicles by membrane targeting 
Loading of cargo into EVs is very difficult. On the one side, the volume of EVs is small 
in relation to a protein. On the other hand, there might be not natural targeting of the 
protein to EVs or the chemical nature of the protein might hamper the localization in 
vesicles.  
Since, in literature successful loading by exogenous and endogenous loading 
approaches have been described, in this project both variants have been challenged. 
The exogenous loading was not successful. One very challenging aspect of cell free 
loading of EVs is the recovery of the vesicles from the drug suspension for removal of 
excessive drug without major loss of particles. This problem is not existing for 
endogenous loading since, the vesicles are recovered by the two-step FPLC protocol 
with the cargo already loaded. For exogenous loading experiments, washing in a 
ultracentrifugation unit was described as suitable for vesicle recovery (Alvarez-Erviti 
et al., 2011). Since precipitated drug molecules could be recovered as well in an 
ultracentrifugation unit, a chromatographic column was used in this project as a 
better alternative. The main advantages are that the vesicles remain intact and do not 
experience mechanical stress, which might be of relevance for the clinical application. 
However, the purification by chromatographic columns does not completely ensure 
the removal of extravesicular cargo; some proteins or molecules of hydrophobic 
nature might stick to the surface of extracellular vesicles and cannot be removed by 
SEC.  
There are publications on efficient exogenous loading of cargo to exosomes. In 
particular, electroporation is up to now the method most often described and 
recommended for introduction of RNA (Marcus and Leonard, 2013). Since 
biomolecules start to aggregate when subjected to an electric field (Kooijmans et al., 
2013), this method is not appropriate for EVs. For cells being transfected by 
electroporation this approach might be suitable since cells can be washed by 
centrifugation with low speed. Transfected cells can be selected by application of a 




work with EVs. And in this study, the approaches with electroporation have not been 
successful.  
There is a company selling a product named ExoFect. Customers are able to introduce 
nucleic acids to self-prepared exosomes, which are then incorporated with the help of 
a chemical substance within 20 minutes. This kit is sold for the transfection of cells. In 
this project, the loading by artificial formation of pores with chemicals and incubation 
with the drug did not result in enrichment within the exosomes.  
Loading of the protein TPPI has not been as successful as needed for in vivo 
experiments. Despite the observation that small amounts of remaining TPPI-activity 
have an influence on disease progression (Wisniewski et al., 2001), the enzyme 
replacement therapy is performed with great amounts of protein corresponding to 
100 mg per injection. For this purpose, TPPI targeting into exosomes was not 
considered in the further project development. 
For protein cargo, endogenous loading approaches appear to be of higher efficiency. 
Two cell lines were investigated for their capacity of packing proteins into exosomes: 
HEK293 and K562. Because of toxins secreted in exosomes by K562 cells (Zhang et al., 
2009), we hoped to observe a similar effect on the overexpressed protein. Almost no 
difference in the relative packaging efficiency of these two cell lines could be 
observed. 
Many groups use proteins enriched in exosomes and tag the drug using for instance 
the C1C2 domain of lactadherin (Zeelenberg et al., 2008) or Lamp2b (Alvarez-Erviti et 
al., 2011). All these tags result in a membrane localization and potentially on the 
surface of the vesicles. However, then the protective effect for the drug protein that is 
a main advantage of exosomes as drug delivery vehicles is reduced due to the 
localization. In the end, the localization of high amounts of PTPS to EVs was 
successfully realized by a similar strategy: engineering a membrane targeting amino 
acid sequence to the N-terminus of PTPS. In this project the neuronal cell associated 
GAP43 membrane targeting sequence was added. With this approach, finally a high 




GAP43 is in vesicles that are transported in the nervous system might enhance the 
feasibility of these vehicles in neurological disorders. However, GAP43-tagging could 
result in a surface localization of PTPS and reduce the capacity of the established drug 
delivery vehicle. The localization on the vesicle surface could be checked by gold 
labeling of PTPS in EM. 
The EVs in the FPLC preparation have a size between 20-200 nm. A protein with 50-
100 kDa has the smallest possible radius of 2.4-3.05 nm (Erickson, 2009). In figure 
4.1, the dimensions and the ratios are depicted for the carrier protein ferritin. This 
image clearly illustrates the limitations of exosomes as delivery vehicles. This 
volumetric capacity must be kept in mind, especially since exosomes cannot be 
concentrated to more than the maximum of 1012 particles/ml. Beyond this particle 
concentration visible aggregates start to form. For this reason, exosomes as drug 
delivery vehicles are limited to disorders in which small amounts of cargo are likely to 
be sufficient. 
 
Figure 4.1: Schematic size demonstration of an exemplary protein, apoferritin, in 
comparison to an exosome modified from Li et al. 
Loading of proteins to vesicles is strongly limited by the volume of the EVs. Additionally, EVs 
are not empty sleeves. There is content like proteins and nucleic acids that are already 




4.3 Uptake of FRα-presenting EVs 
The FRα is used as a common tool in drug targeting (Sudimack and Lee, 2000). FRα is 
utilized in two manners: either FRα-targeted antibodies or antifolates are conjugated 
to the drug. FRα is present in the choroid plexus and for example in related 
malignancies. Several groups published FRα as a protein present in exosomes 
(Admyre et al., 2007, Raj et al., 2012). Grapp et al. could prove that FRα-presenting 
exosomes are distributed throughout the whole brain parenchyma (Grapp et al., 
2013). Most likely, FRα stabilizes 5MTHF and promotes its transport and distribution 
throughout the brain parenchyma.  
Exosomes are mainly taken up by four mechanisms: endocytosis, micropinocytosis or 
phagocytosis and fusion with the up taking cell (McKelvey et al., 2015). To investigate 
the FRα mediated transepithelial transport, the cell line BN16 from rat egg yolk was 
chosen. BN16 cells are expressing megalin and it was published that FR is colocalizing 
with megalin (Birn et al., 1997) and soluble FR is internalized by megalin (Birn et al., 
2005).  
Analyzing the biological activity of the vesicles a higher uptake of FRα-positive 
vesicles in comparison to native EVs could be proven. Therefore, these results with 
BN16 cells might confirm the hypothesis that the receptor and the vesicles are taken 
up by megalin. To further investigate the uptake mechanism uptake experiments with 
other cell types should be performed. Moreover, it would be very interesting to image 
the uptake with the help of microscopic tools. Once, the EVs reached the cells it is 
unclear how they are processed. For the treatment of lysosomal disorders, a 
procession to the lysosome would be advantage but for the biopterin disorder, it 
would be a terrible failure. However, the establishment of a FRα-decorated and 
chargeable drug vehicle enlarges the possibility of FRα-based therapy. 
4.4 Biodistribution of intranasally administered exosomes 
Exosomes are natural occurring vesicles that resemble liposomes. In the liposome 




but are fully artificial. Therefore, these designed vesicles are easier to modify, the lipid 
composition can be influenced, hydrophilic molecules can be loaded inside the 
liposomes, and lipophilic ones can be localized to the membrane. Furthermore, the 
size can be influenced. Exosomes are more difficult to modify than liposomes, but 
exosomes provide the biological stability and compatibility.  
Liposomes are mainly processed by macrophages in the liver. PEG-coated liposomes 
have a longer circulation time in the blood and are also taken up by other tissues 
(Immordino et al., 2006). Larger particles, ≥250 nm are retrieved in the spleen. This 
results from fibers running parallel to the blood vessel of the spleen. They are 
organized in approximately 250 nm distance for filtering of older and more rigid 
blood cells (van der Meel et al., 2014). 
In contrary to a lipophilic dye, the used dye IRDye800 that was attached by an amide 
bond to proteins on the surface of the vesicles. This way, a flipping of the dye to other 
membranes is unlikely, but the observed distribution, might result from dye 
distribution and not from exosome distribution. The dye might be taken up and 
processed by macrophages inside the tissue. The dye-control in this experiment has a 
peak of 6/12 h after application inside the liver, the kidney but also in the brain. This 
seems to be a systemic presence of the dye. The vesicles in contrary show an increase 
in the liver 24 h after application. This corresponds to the behavior of long circulating 
liposomes applied intravenously (van der Meel et al., 2014) implies that the vesicles 
have a longer circulation time than the dye itself. Even though the exosomes are of 
greater size, no signal could be detected in the spleen. 
In another project, intranasally applied exosomes were tracked in the brain and 
showed a similar behavior: their concentration was highest one hour after application 
and then steadily decreased (Zhuang et al., 2011). The peak observed in several 
organs in our experiment after 12 h was not described. In this project, the distribution 
was assessed by measuring the concentration of curcumin, which was inside the 
vesicles. Our results indicate that the administration and the targeting of exosomes to 




Resulting from the limited knowledge on cellular uptake of exosomes, the distribution 
in organs is even less understood. There are publications in which virus-derived 
proteins or peptides like the central nervous system-specific rabies viral glycoprotein 
peptide were able to enter neuronal cells (Alvarez-Erviti et al., 2011). The FRα-
presenting vesicles behaved in the in vivo experiment similar to the negative vesicles. 
The better uptake of FRα-presenting vesicles observed in a cell culture line of 
epithelial cells, BN16, could not be reproduced in mouse.  
4.5 Drug delivery capacity of PTPS carrying and FRα-presenting exosomes 
To finally investigate the drug delivery capacity of the established vehicle system, the 
PTPS deficient mouse model was chosen. The mice were treated by oral and by 
intranasal application. Other administration options are not suitable because of the 
age, the small size of the KO and repetitive nature of the EV based therapy. 
While the disease progression could not be intervened by oral administration the 
intranasal application showed positive effects on the growth and the performance in 
the behavioral assay of the KO mice. In the fourth week after birth even a significant 
higher BW in comparison to not EV-treated KO mice could be measured. Introducing 
an EV-based drug delivery of an enzyme replacement therapy to a neurodegenerative 
mouse model, the disease progression could be slowed down. The mice showed a 
significant improvement in comparison to the not EV-treated mice. The delivery of the 
enzyme depends on exosomes since in the control animal being treated only with the 
enzyme no effect was observed.  
The efficiency in treatment was observed by the gain in the BW as well as in the 
improved performance and motor coordination of the treated mice. The mice were 
not more active, but fitter and able to perform better than the control mice in the Rota 
Rod experiment. The overall performance of the mice increased significantly in 
contrary to the not EV-treated KO mice. Further, the EV-treated mice could not be 
distinguished from healthy mice in the first week after birth. In the continuing weeks 




Considering the set of symptoms, the disease onset could be postponed and the 
progression slowed down. 
The vesicles were applied by intranasal route. The therapeutic capacity of the 
exosomes seemed to decrease with the age of the animals. This observation might 
have different causes. The neurodegenerative effect of a PTPS-deficiency is decreasing 
with age. For this reason, the curative efficiency of a PTPS replacement therapy might 
be less efficient. Also the amount of intranasally applicable EV suspension is limited to 
10 µl for animal protection reasons. Maybe at this point the amount of treatment was 
not sufficient anymore. 
4.6 Outlook 
This project describes the first successful approach to treat an enzyme deficiency by 
exosome delivery therapy. There are publications on the capacity of exosomes to 
deliver supportive small molecules to improve healing or to reduce resistance 
towards administered drugs. For this purpose, this project implies an important proof 
of concept for the therapeutic application of EVs. However, there are still more 
experiments required to characterize this therapeutic delivery system. 
One central question that still needs to be clarified is the role and significance of the 
folate receptor. It is conceivable that not modified vesicles might have a similar effect 
for drug delivery to the CNS. It might be that the measured effect is related to the 
small amount of vesicles that are able to leak through the inefficient barrier of the 
olfactory bulb no matter with or without the FRα expression.  
Apart from the EVs, there will be experiments with artificial NPs presenting FRα. 
These particles are being equipped with sepiapterin. Their behavior in similar 
experiments in comparison to pristine NPs, resolving their uptake as well as the 
biological performance will shed light on the importance of FRα. In case the 
nanoparticles show similar or even better efficiency in the mouse model this would 
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